faculty.mdanderson.org
Open in
urlscan Pro
143.111.156.80
Public Scan
URL:
https://faculty.mdanderson.org/profiles/banu_arun.html
Submission: On April 26 via manual from US — Scanned from DE
Submission: On April 26 via manual from US — Scanned from DE
Form analysis 2 forms found in the DOM
Name: nav-search —
<form name="nav-search" id="nav-search-form" class="mda-nav-search-form">
<i aria-hidden="true" class="search-icon mda-icon-search"></i>
<label class="search-label" for="site-search">Search</label>
<input type="text" class="mda-nav-search-field search-field" id="site-search" size="1" placeholder="Search">
<div class="mda-nav-search-clear search-clear"><a id="nav-search-clear" href="#" role="button">Clear</a></div>
<button type="submit" class="mda-nav-search-submit mda-btn">Go</button>
</form>Name: nav-search —
<form name="nav-search" id="nav-search-form-svp" class="mda-nav-search-form" role="search">
<div class="mda-nav-search-input-wrapper">
<i aria-hidden="true" class="search-icon mda-icon-search"></i>
<label for="nav-search-form-svp-input" class="visuallyhidden">Search MD Anderson</label>
<input id="nav-search-form-svp-input" type="text" class="mda-nav-search-field search-field" size="1" placeholder="Search MD Anderson">
<div class="mda-nav-search-clear search-clear">
<button type="button" id="nav-search-clear-from-siteheader">Clear</button>
</div>
</div>
<button type="submit" class="mda-nav-search-submit mda-btn" aria-label="Search">Go</button>
</form>Text Content
Please click here if you are not redirected within a few seconds.
Skip to Content
* MyChart
Log in to our secure, personalized website to manage your care (formerly
myMDAnderson).
* Request an Appointment
REQUEST AN APPOINTMENT
If you are ready to make an appointment, select a button on the right. If you
have questions about MD Anderson’s appointment process, our information page
may be the best place to start.
Appointment Information
New Patients Current Patients Referring Physicians
* Donate Today
Menu Close
* Clinical Trials
* Locations
* Careers
* Contact Us
* Our Doctors
* Languages
* Español
* عربى
* 中文
* Türkçe
Search
Clear
Go
close
Search MD Anderson
Clear
Go
MyChart
Donate Today
* Clinical Trials
* Locations
* Careers
* Contact Us
* Languages
* Español
* عربى
* 中文
* Türkçe
Request an Appointment
* Request an Appointment
* New Patients
* Current Patients
* Referring Physicians
* Patients & Family
* Becoming Our Patient
* Becoming Our Patient
* Becoming Our Patient Home
* Why MD Anderson
* Planning for Care
* Getting to MD Anderson
* While You're Here
* International Center
* Services and Amenities
* Insurance & Billing
* Diagnosis & Treatment
* Diagnosis & Treatment
* Diagnosis & Treatment Home
* Cancer Types
* A New Diagnosis
* Treatment Options
* Care Centers & Clinics
* Emotional & Physical Effects
* Patient Support
* Clinical Trials
* Supporting a Loved One
* Supporting a Loved One
* Supporting a Loved One Home
* Caregiver Roles & Challenges
* Children and Teens
* Taking Care of Yourself
* Helping an MD Anderson Patient
* Dealing with Loss
* Life After Cancer
* Life After Cancer
* Life After Cancer Home
* Legal & Financial Impacts of Cancer
* Social & Emotional Impacts of Cancer
* Follow-up Care
* Long-Term Effects of Cancer
* Survivorship Week
* Request an Appointment Current Patients
Find information and resources for current and returning patients.
Clinical Trials
Learn about clinical trials at MD Anderson and search our database for
open studies.
* Prevention & Screening
* Manage Your Risk
* Manage Your Risk
* Manage Your Risk Home
* Tobacco Control
* Diet
* Body Weight
* Physical Activity
* Skin Safety
* HPV
* Hepatitis
* Family History
* Family History
* Family History Home
* Genetic Testing
* Hereditary Cancer Syndromes
* Genetic Counseling and Testing FAQs
* Cancer Screenings
* Cancer Screenings
* Cancer Screenings Home
* Mammograms & Breast Cancer Screening
* Cervical Cancer Screening
* Colorectal Cancer Screening
* Endometrial Cancer Screening
* Liver Cancer Screening
* Lung Cancer Screening
* Mobile Mammography
* Ovarian Cancer Screening
* Prostate Cancer Screening
* Skin Cancer Screening
* Women's Cancer Screening
* Men's Cancer Screening
* Cancer Prevention Center
The Lyda Hill Cancer Prevention Center provides cancer risk assessment,
screening and diagnostic services.
* Donors & Volunteers
* Donate
* Donate
* Donate Home
* Raise Money
* Honor Loved Ones
* Create Your Legacy
* Endowments
* Caring Fund
* Matching Gifts
* Volunteer
* Volunteer
* Volunteer Home
* On-Site Volunteers
* Volunteer Endowment
* Patient Experience
* Teen Volunteer Leadership Program
* Children's Cancer Hospital Councils
* Other Ways to Help
* Other Ways to Help
* Other Ways to Help Home
* Give Blood
* Shop MD Anderson
* Children's Art Project
* Donate Goods or Services
* Attend Events
* Cord Blood Bank
* Corporate Alliances
* Corporate Alliances
* Corporate Alliances Home
* Current Alliances
* Donate Today
Your gift will help support our mission to end cancer and make a
difference in the lives of our patients.
* For Physicians
* Refer a Patient
* Refer a Patient
* Refer a Patient Home
* Health Care Provider Resource Center
* Referring Provider Team
* Insurance Information
* International Referrals
* myMDAnderson for Physicians
* Second Opinion Pathology
* Clinical Trials
* Clinical Trials
* Clinical Trials Home
* Clinical Tools & Resources
* Clinical Tools & Resources
* Clinical Tools & Resources Home
* Clinical Calculators
* Clinical Practice Algorithms
* myMDAnderson for Physicians
Our personalized portal helps you refer your patients and communicate with
their MD Anderson care team.
* Research
* Departments, Labs and Institutes
* Departments, Labs and Institutes
* Departments, Labs and Institutes Home
* Departments and Divisions
* Labs
* Research Centers and Programs
* Institutes
* Specialized Programs of Research Excellence (SPORE) Grants
* Research Areas
* Research Areas
* Research Areas Home
* Basic Science
* Translational Research
* Clinical Research
* Prevention & Personalized Risk Assessment
* Research Resources
* Research Resources
* Research Resources Home
* Excellence in Science
* Core Facilities and Services
* Office of Clinical Research
* Office of Sponsored Programs
* Office of Research Administration
* Conferences & Seminars
* Clinical Trials
As part of our mission to eliminate cancer, MD Anderson researchers
conduct hundreds of clinical trials to test new treatments for both common
and rare cancers.
* Education & Training
* Degree-Granting Schools
* Degree-Granting Schools
* Degree-Granting Schools Home
* School of Health Professions
* MD Anderson UTHealth Houston Graduate School
Education Resources
* Education Resources
* Education Resources Home
* Alumni Relations
* TIPS Education Center
* Awards & Recognitions
* Academic Mentoring Council
* Why MD Anderson & Houston
* Research Training
* Research Training
* Research Training Home
* Early Career Pathway Programs
* Predoctoral Training
* Postdoctoral Training
* Mentored Faculty Programs
* Career Development
* Clinical Training
* Clinical Training
* Clinical Training Home
* Graduate Medical Education
* Clinical Education for Non-Physicians
* Nursing Education & Training
* Certificate Programs & Review Courses
* Skills Training & Simulation
* Continuing Education & Professional Development
* Continuing Education & Professional Development
* Continuing Education & Professional Development Home
* Continuing Professional Education/Conferences
* Administrative Internships & Fellowships
* Cancer Survivorship Professional Education
* Leadership Institute
Outreach Programs
* Outreach Programs
* Outreach Programs Home
* Project ECHO
* Observer Programs
* Comparative Effectiveness Training (CERTaIN)
* Apply to SHP
Choose from 12 allied health programs at School of Health Professions.
Research Trainees
View open postdoctoral and other research trainee positions.
GME Fellowships
Learn about our graduate medical education residency and fellowship
opportunities.
Top
BANU ARUN, MD
Department of Breast Medical Oncology, Division of Cancer Medicine
IN THE NEWS
IS BREAST CANCER GENETIC?
ASCO RECOGNIZES THREE MD ANDERSON FACULTY WITH HIGHEST HONORS
GENETIC TESTING FOR CANCER RISK: INSIGHT FOR HEALTH CARE...
Read more news Read less news
PRESENT TITLE & AFFILIATION
PRIMARY APPOINTMENT
Professor (Tenure), Department of Breast Medical Oncology, Division of Cancer
Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
DUAL/JOINT/ADJUNCT APPOINTMENT
Professor (Tenure), Department of Clinical Cancer Prevention, Division of OVP,
Cancer Prevention and Population Sciences, The University of Texas MD Anderson
Cancer Center, Houston, TX
Faculty, The University of Texas Graduate School of Biomedical Sciences,
Houston, TX
RESEARCH INTERESTS
Dr. Banu Arun is a Professor in the Department of Breast Medical Oncology at The
University of Texas MD Anderson Cancer Center. Dr. Arun is also Co-Medical
Director of the Clinical Cancer Genetics Program. Her research interests include
breast cancer treatment, biological markers, chemoprevention, and breast cancer
genetics. Her laboratory and clinical research include characterization of risk
factors in high-risk women with or without deleterious BRCA mutations and
assessing breast cancer biology in patients with breast cancer who have
mutations of the BRCA1 or BRCA2 gene. Dr. Arun has served as the Principal
Investigator of several phase II breast cancer prevention trials with agents
such as celecoxib, atorvastatin and targretin, and also breast cancer trials
with PARP inhibitors. Dr. Arun serves as a member for ASCO BOLD Task Force, NCCN
breast cancer risk assessment committee member. Dr. Arun serves also as an SWOG
Co-Chair for the Prevention Committee.
EDUCATION & TRAINING
DEGREE-GRANTING EDUCATION
1990University of Istanbul, Cerrahpasa Medical School, Istanbul, TUR, MD
POSTGRADUATE TRAINING
1994-1997Fellowship, Hematology and Oncology, Vincent T. Lombardi Cancer Center
Georgetown University, Washington1990-1994Residency, Internal Medicine,
University of Istanbul, Cerrahpasa Medical School, Istanbul
BOARD CERTIFICATIONS
2010Diplomat, American Board of Internal Medicine
EXPERIENCE & SERVICE
ADMINISTRATIVE APPOINTMENTS/RESPONSIBILITIES
Chief, Section of Genetics, Prevention and Early Detection, Department of Breast
Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston,
TX, 2015 - Present
INSTITUTIONAL COMMITTEE ACTIVITIES
Panel Member, NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and
Pancreatic, 2022 - Present
Member, Breast Center Steering Committee, 2015 - Present
Member, Breast Medical Oncology Steering Committee, 2015 - Present
HONORS & AWARDS
2023Ashbel Smith Professorship, University of Texas MD Anderson Cancer
Center2020Fellow of the American Society of Clinical Oncology, American Society
of Clinical Oncology (ASCO)
PROFESSIONAL MEMBERSHIPS
American Society of Clinical Oncology, Chicago, IL
Planning Committee Member-Genetics and Genomics for the Practicing Clinician,
2019 - 2019
SELECTED PUBLICATIONS
PEER-REVIEWED ARTICLES
1. Makhnoon S, Arun B, Bedrosian I. Helping patients understand and cope with
BRCA mutations. Curr Oncol Rep 24(6):733-40, 2022. PMID: 35303253.
2. Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Parra Cuentas ER, Garber
H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf
EA, Litton JK. Tumor immune microenvironment changes by multiplex
immunofluorescence staining in a pilot study of neoadjuvant talazoparib
for early-stage breast cancer patients with a hereditary BRCA mutation.
Clin Cancer Res, 2022. e-Pub 2022. PMID: 35736816.
3. Liu X, Ge Z, Yang F, Contreras A, Lee S, White JB, Lu Y, Labrie M, Arun
BK, Moulder SL, Mills GB, Piwnica-Worms H, Litton JK, Chang JT.
Identification of biomarkers of response to preoperative talazoparib
monotherapy in treatment naïve gBRCA+ breast cancers. NPJ Breast Cancer
8(1):64, 2022. PMID: 35538088.
4. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE,
Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno
NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM,
Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT.
Molecular characterization and prospective evaluation of pathological
response and outcomes with neoadjuvant therapy in metaplastic
triple-negative breast cancer. Clin Cancer Res, 2022. e-Pub 2022. PMID:
35507014.
5. Garber HR, Raghavendra AS, Lehner M, Qiao W, Gutierrez-Barrera AM,
Tripathy D, Arun B, Ibrahim NK. Incidence and impact of brain metastasis
in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer.
NPJ Breast Cancer 8(1):46, 2022. PMID: 35393462.
6. Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA,
Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun
BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D,
Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ,
Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD,
Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto
R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK,
Claes KBM, Colonna S; GEMO Study Collaborators; GC-HBOC Study
Collaborators; EMBRACE Collaborators, Cook LS, Couch FJ, Daly MB, Dao F,
Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez
O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM,
Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT,
Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon
G, Godwin AK, Goodman MT, Greene MH, Gronwald J; OPAL Study Group; AOCS
Group, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR,
Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL,
Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN; KConFab
Investigators; HEBON Investigators, Isaacs C, Jakubowska A, James PA,
Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan
BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeney LA, Kim BG, Kjaer
SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson
MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J,
Loud JT, Lu KH, Lubiński J, Mai PL, Manoukian S, Marks JR, Matsuno RK,
Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon
U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB,
Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR,
Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S,
Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons.
Correction: Polygenic risk modeling for prediction of epithelial ovarian
cancer risk. Eur J Hum Genet, 2022. e-Pub 2022. PMID: 35314806.
7. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R
Jr, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J,
Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb
S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D,
Moulder S, Huo L. Prognostic impact of high baseline stromal
tumor-infiltrating lymphocytes in the absence of pathologic complete
response in early-stage triple-negative breast cancer. Cancers (Basel)
14(5):1323, 2022. PMID: 35267631.
8. Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA,
Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun
BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D,
Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ,
Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD,
Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto
R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK,
Claes KBM, Colonna S; GEMO Study Collaborators; GC-HBOC Study
Collaborators; EMBRACE Collaborators, Cook LS, Couch FJ, Daly MB, Dao F,
Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez
O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM,
Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT,
Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon
G, Godwin AK, Goodman MT, Greene MH, Gronwald J; OPAL Study Group; AOCS
Group, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR,
Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL,
Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN; KConFab
Investigators; HEBON Investigators, Isaacs C, Jakubowska A, James PA,
Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan
BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeney LA, Kim BG, Kjaer
SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson
MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J,
Loud JT, Lu KH, Lubiński J, Mai PL, Manoukian S, Marks JR, Matsuno RK,
Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon
U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB,
Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR,
Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S,
Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons.
Polygenic risk modeling for prediction of epithelial ovarian cancer risk.
Eur J Hum Genet 30(3):349-62, 2022. PMID: 35027648.
9. an HS, Arun BK, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla
SL, Bach BA, Kundu MG, Khandelwal N, Feng D, Bhattacharya S, Maag D,
Ratajczak CK, Diéras V. Veliparib monotherapy following
carboplatin/paclitaxel plus veliparib combination therapy in patients with
germline BRCA-associated advanced breast cancer: results of exploratory
analyses from the phase III BROCADE3 trial. Ann Oncol 33(3):299-309, 2022.
PMID: 34861374.
10. Layman RM, Lin H, Gutierrez Barrera AM, Karuturi MS, Yam C, Arun BK.
Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage
BRCA-associated hormone receptor-positive breast cancer. Cancer Med, 2022.
e-Pub 2022. PMID: 35128817.
11. Basen-Engquist K, Raber M, Strong LL, Schembre S, Li L, Arun B, Lu K, You
N, Vilar E, Lynch P, Fares S, Peterson SK. Optimization of an mHealth
lifestyle intervention for families with hereditary cancer syndromes:
Study protocol for a multiphase optimization strategy feasibility study.
Contemp Clin Trials 113:106662, 2022. e-Pub 2021. PMID: 34971795.
12. Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein
SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward
WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF.
Breast radiation therapy-related treatment outcomes in patients with or
without germline mutations on multigene panel testing. Int J Radiat Oncol
Biol Phys 112(2):437-44, 2022. PMID: 34582940.
13. Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein
SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward
WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF.
Outcomes after breast radiation therapy in a diverse patient cohort with a
germline BRCA1/2 mutation. Int J Radiat Oncol Biol Phys 112(2):426-36,
2022. PMID: 34610390.
14. Arun BK, Peterson SK, Sweeney LE, Bluebond RD, Tidwell RSS, Makhnoon S,
Kushwaha AC. Increasing referral of at-risk women for genetic counseling
and BRCA testing using a screening tool in a community breast imaging
center. Cancer 128(1):94-102, 2022. PMID: 34424535.
15. Siettmann JM, Arun B, Gasparini J, Mina LA. Personalized breast cancer
risk assessment: incorporation of genetic and high-risk factorson breast
cancer risk and management. Chirurgia (Bucur) 116(5 Suppl):S22-S34, 2021.
PMID: 34967308.
16. Al-Shamsi HO, Abu-Gheida I, Abdulsamad AS, AlAwadhi A, Alrawi S, Musallam
KM, Arun B, Ibrahim NK. Molecular spectra and fequency patterns of somatic
mutations in arab women with breast cancer. Oncologist 26(11):e2086-e2089,
2021. e-Pub 2021. PMID: 34327780.
17. Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA,
Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip CH, Ghosn M,
Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, Gligorov J,
Gulluoglu BM, Abdel Aziz H, Frolova M, Sabry M, Balch CM, Orecchia R,
El-Zawahry HM, Al-Sukhun S, Abdel Karim K, Kandil A, Paltuev RM, Foheidi
M, El-Shinawi M, ElMahdy M, Abulkhair O, Yang W, Aref AT, Bakkach J, Bahie
Eldin N, Elghazawy H. Breast-gynaecological & immuno-oncology
international cancer conference (BGICC) consensus and recommendations for
the management of triple-negative breast cancer. Cancers (Basel)
13(9):2262, 2021. PMID: 34066769.
18. Murphy BL, Yi M, Arun BK, Gutierrez Barrera AM, Bedrosian I. Contralateral
risk-reducing mastectomy in breast cancer patients who undergo multigene
panel testing. Ann Surg Oncol 27(12):4613-21, 2020. e-Pub 2020. PMID:
32720048.
19. Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla
SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M,
Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak
CK, Maag D, Arun BK. Veliparib with carboplatin and paclitaxel in
BRCA-mutated advanced breast cancer (BROCADE3): a randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet Oncol
21(10):1269-82, 2020. e-Pub 2020. PMID: 32861273.
20. Damodaran S, Sember QC, Arun BK. Clinical implications of breast cancer
tumor genomic testing. Breast J 26(8):1565-71, 2020. e-Pub 2020. PMID:
32696498.
21. Fahrmann JF, Vykoukal J, Fleury A, Tripathi S, Dennison JB, Murage E, Wang
P, Yu CY, Capello M, Creighton CJ, Do KA, Long JP, Irajizad E, Peterson C,
Katayama H, Disis ML, Arun B, Hanash S. Association between plasma
diacetylspermine and tumor spermine synthase with outcome in triple
negative breast cancer. J Natl Cancer Inst 112(6):607-16, 2020. e-Pub
2019. PMID: 31503278.
22. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y,
Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G,
Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL,
Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun
BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez
J, Benlloch S, Berchuck A, Berndt SI, Bickeböller H, Bien SA, Blomqvist C,
Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton
JD, Brook MN, Brunet J, Brunnström H, Buchanan DD, Burwinkel B, Butzow R,
Cadoni G, Caldés T, Caligo MA, Campbell I, Campbell PT, Cancel-Tassin G,
Cannon-Albright L, Campa D, Caporaso N, Carvalho AL, Chan AT, Chang-Claude
J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J,
Collée JM, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K,
Daly MB, deFazio A, Devilee P, Diez O, Gago-Dominguez M, Donovan JL, Dörk
T, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV,
Ellberg C, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC,
Fletcher O, Fortner RT, Fostira F, Franceschi S, Friedman E, Gallinger SJ,
Ganz PA, Garber J, García-Sáenz JA, Gayther SA, Giles GG, Godwin AK,
Goldberg MS, Goldgar DE, Goode EL, Goodman MT, Goodman G, Grankvist K,
Greene MH, Gronberg H, Gronwald J, Guénel P, Håkansson N, Hall P, Hamann
U, Hamdy FC, Hamilton RJ, Hampe J, Haugen A, Heitz F, Herrero R,
Hillemanns P, Hoffmeister M, Høgdall E, Hong YC, Hopper JL, Houlston R,
Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Imyanitov EN, Ingles SA, Isaacs
C, Jakubowska A, James P, Jenkins MA, Johansson M, Johansson M, John EM,
Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Kühl T, Khaw KT, Khusnutdinova
E, Kibel AS, Kiemeney LA, Kim J, Kjaer SK, Knight JA, Kogevinas M,
Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S,
Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkowicz F, Lenz HJ,
Leslie G, Lessel D, Lester J, Levine D, et al. Shared heritability and
functional enrichment across six solid cancers. Nat Commun 10(1):431,
2019. PMID: 30683880.
23. Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM,
Bast RC Jr, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN,
Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in
patients with hormone receptor-positive metastatic breast cancer
expressing c-kit or PDGFR-β. Invest New Drugs 36(6):1103-1109, 2018. e-Pub
2018. PMID: 30311036.
24. Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A,
Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V,
Pérez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R,
Arribas J, Vivancos A, Baselga J, Serra V, Balmaña J, Isakoff SJ.
Multicenter phase II study of lurbinectedin in BRCA-mutated and unselected
metastatic advanced breast cancer and biomarker assessment substudy. J
Clin Oncol 36(31):3134-3143, 2018. e-Pub 2018. PMID: 30240327.
25. Qian F, Wang S, Mitchell J, McGuffog L, Barrowdale D, Leslie G, Oosterwijk
JC, Chung WK, Evans DG, Engel C, Kast K, Aalfs CM, Adank M, Adlard J,
Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Arun BK, Ausems MGEM,
Azzollini J, Barouk-Simonet E, Barwell J, Belotti M, Benitez J, Berger A,
Borg A, Bradbury AR, Brunet J, Buys SS, Caldes T, Caligo MA, Campbell I,
Caputo SM, Chiquette J, Claes KBM, Margriet Collée J, Couch FJ, Coupier I,
Daly MB, Davidson R, Diez O, Domchek SM, Donaldson A, Dorfling CM, Eeles
R, Feliubadaló L, Foretova L, Fowler J, Friedman E, Frost D, Ganz PA,
Garber J, Garcia-Barberan V, Glendon G, Godwin AK, Gómez Garcia EB,
Gronwald J, Hahnen E, Hamann U, Henderson A, Hendricks CB, Hopper JL,
Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Izquierdo Á, Jakubowska A,
Kaczmarek K, Kang E, Karlan BY, Kets CM, Kim SW, Kim Z, Kwong A, Laitman
Y, Lasset C, Hyuk Lee M, Won Lee J, Lee J, Lester J, Lesueur F, Loud JT,
Lubinski J, Mebirouk N, Meijers-Heijboer HE, Meindl A, Miller A, Montagna
M, Mooij TM, Morrison PJ, Mouret-Fourme E, Nathanson KL, Neuhausen SL,
Nevanlinna H, Niederacher D, Nielsen FC, Nussbaum RL, Offit K, Olah E, Ong
KR, Ottini L, Park SK, Peterlongo P, Pfeiler G, Phelan CM, Poppe B,
Pradhan N, Radice P, Ramus SJ, Rantala J, Robson M, Rodriguez GC,
Schmutzler RK, Hutten Selkirk CG, Shah PD, Simard J, Singer CF, Sokolowska
J, Stoppa-Lyonnet D, Sutter C, Yen Tan Y, Teixeira RM, Teo SH, Terry MB,
Thomassen M, Tischkowitz M, Toland AE, Tucker KM, Tung N, van Asperen CJ,
van Engelen K, van Rensburg EJ, Wang-Gohrke S, Wappenschmidt B, Weitzel
JN, Yannoukakos D, GEMO Study Collaborators; HEBON; EMBRACE, Greene MH,
Rookus MA, Easton DF, Chenevix-Trench G, Antoniou AC, Goldgar DE, Olopade
OI, Rebbeck TR, Huo D. Height and Body Mass Index as Modifiers of Breast
Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.
J Natl Cancer Inst. e-Pub 2018. PMID: 30312457.
26. Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B, Schildkraut JM, Im HK, Chen YA,
Permuth JB, Reid BM, Teer JK, Moysich KB, Andrulis IL, Anton-Culver H,
Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Benitez J, Bjørge L,
Brenton J, Butzow R, Caldes T, Caligo MA, Campbell IG, Chang-Claude J,
Claes KBM, Couch FJ, Cramer DW, Daly MB, DeFazio A, Dennis J, Díez O,
Domchek SM, Dork T, Easton DF, Eccles DM, Fasching PA, Fortner RT,
Fountzilas G, Friedman E, Ganz PA, Garber J, Giles GG, Godwin AK, Goldgar
DE, Goodman MT, Greene MH, Gronwald J, Hamann U, Heitz F, Hildebrandt MAT,
Høgdall CK, Hollestelle A, Hulick PJ, Huntsman DG, Imyanitov EN, Isaacs C,
Jakubowska A, James P, Karlan BY, Kelemen LE, Kiemeney LA, Kjaer SK, Kwong
A, Le ND, Leslie G, Lesueur F, Levine DA, Mattiello A, May T, McGuffog L,
McNeish IA, Merritt MA, Modugno F, Montagna M, Neuhausen SL, Nevanlinna H,
Cilius Nielsen FC, Nikitina-Zake L, Nussbaum RL, Offit K, Olah E, Olopade
OI, Olson SH, Olsson H, Osorio A, Park SK, Parsons MT, Peeters PHM,
Pejovic T, Peterlongo P, Phelan CM, Pujana MA, Ramus SJ, Rennert G, Risch
H, Rodriguez GC, Rodríguez-Antona C, Romieu I, Rookus MA, Rossing MA,
Rzepecka IK, Sandler DP, Schmutzler RK, Setiawan VW, Sharma P, Sieh W,
Simard J, Singer CF, Song H, Southey MC, Spurdle AB, Sutphen R, Swerdlow
AJ, Teixeira MR, Teo SH, Thomassen M, Tischkowitz M, Toland AE,
Trichopoulou A, Tung N, Tworoger SS, van Rensburg EJ, Vanderstichele A,
Vega A, Velez Edwards D, Webb PM, Weitzel JN, Wentzensen N, White E, Wolk
A, Wu AH, Yannoukakos D, Zorn KK, Gayther SA, Antoniou AC, Berchuck A,
Goode EL, Chenevix-Trench G, Sellers TA, Pharoah PDP, Zheng W, Long J. A
transcriptome-wide association study among 97,898 women to identify
candidate susceptibility genes for epithelial ovarian cancer risk. Cancer
Res. e-Pub 2018. PMID: 30054336.
27. Chowdhury M, Euhus D, Arun B, Umbricht C, Biswas S, Choudhary P.
Validation of a personalized risk prediction model for contralateral
breast cancer. Breast Cancer Res Treat 170(2):415-23, 2018. e-Pub 2018.
PMID: 29574637.
28. Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK,
Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B,
Tripathy D, Ibrahim NK. Development of CNS metastases and survival in
patients with inflammatory breast cancer. Cancer 124(11):2299-2305, 2018.
e-Pub 2018. PMID: 29579338.
29. Elsayegh N, Webster RD, Gutierrez Barrera AM, Lin H, Kuerer HM, Litton JK,
Bedrosian I, Arun BK. Contralateral prophylactic mastectomy rate and
predictive factors among patients with breast cancer who underwent
multigene panel testing for hereditary cancer. Cancer Med 7(6):2718-26,
2018. e-Pub 2018. PMID: 29733510.
30. Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker
CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK,
Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross
HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Safety and
Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With
Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. e-Pub 2018.
PMID: 29879283.
31. Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, Olah E,
Olopade OI, Solano AR, Teo SH, Thomassen M, Weitzel JN, Chan TL, Couch FJ,
Goldgar DE, Kruse TA, Palmero EI, Park SK, Torres D, van Rensburg EJ,
McGuffog L, Parsons MT, Leslie G, Aalfs CM, Abugattas J, Adlard J, Agata
S, Aittomäki K, Andrews L, Andrulis IL, Arason A, Arnold N, Arun BK,
Asseryanis E, Auerbach L, Azzollini J, Balmaña J, Barile M, Barkardottir
RB, Barrowdale D, Benitez J, Berger A, Berger R, Blanco AM, Blazer KR,
Blok MJ, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS,
Caldes T, Caliebe A, Caligo MA, Campbell I, Caputo SM, Chiquette J, Chung
WK, Claes KBM, Collée JM, Cook J, Davidson R, de la Hoya M, De Leeneer K,
de Pauw A, Delnatte C, Diez O, Ding YC, Ditsch N, Domchek SM, Dorfling CM,
Velazquez C, Dworniczak B, Eason J, Easton DF, Eeles R, Ehrencrona H,
Ejlertsen B; EMBRACE, Engel C, Engert S, Evans DG, Faivre L, Feliubadaló
L, Ferrer SF, Foretova L, Fowler J, Frost D, Galvão HCR, Ganz PA, Garber
J, Gauthier-Villars M, Gehrig A; GEMO Study Collaborators, Gerdes AM,
Gesta P, Giannini G, Giraud S, Glendon G, Godwin AK, Greene MH, Gronwald
J, Gutierrez-Barrera A, Hahnen E, Hauke J; HEBON, Henderson A, Hentschel
J, Hogervorst FBL, Honisch E, Imyanitov EN, Isaacs C, Izatt L, Izquierdo
A, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Vijai J,
Kaczmarek K, Karlan BY, Kast K, Investigators K, Kim SW, Konstantopoulou
I, Korach J, Laitman Y, Lasa A, Lasset C, Lázaro C, Lee A, Lee MH, Lester
J, Lesueur F, Liljegren A, Lindor NM, Longy M, Loud JT, Lu KH, Lubinski J,
Machackova E, Manoukian S, Mari V, Martínez-Bouzas C, Matrai Z, Mebirouk
N, Meijers-Heijboer HEJ, Meindl A, Mensenkamp AR, Mickys U, Miller A,
Montagna M, Moysich KB, Mulligan AM, Musinsky J, Neuhausen SL, Nevanlinna
H, Ngeow J, Nguyen HP, Niederacher D, Nielsen HR, Nielsen FC, Nussbaum RL,
Offit K, Öfverholm A, Ong KR, Osorio A, Papi L, Papp J, Pasini B, Pedersen
IS, Peixoto A, . . .Nathanson KL. Mutational spectrum in a worldwide study
of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39(5):593-620,
2018. e-Pub 2018. PMID: 29446198.
32. Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU,
Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of
tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs
36(2):299-306, 2018. e-Pub 2018. PMID: 29374384.
33. Arun BK, Gutierrez Barrera AM, Ueno NT. Reply to Diagnosis of patients
with inflammatory breast cancer is a problematic issue. Cancer 124(4):866,
2018. e-Pub 2017. PMID: 29266209.
34. Clifton K, Gutierrez-Barrera A, Ma J, Bassett R Jr., Litton J, Kuerer H,
Moulder S, Albarracin C, Hortobagyi G, Arun B. Adjuvant versus neoadjuvant
chemotherapy in triple-negative breast cancer patients with BRCA
mutations. Breast Cancer Res Treat. e-Pub 2018. PMID: 29470805.
35. Abdel-Razeq H, Al-Omari A, Zahran F, Arun B. Germline BRCA1/BRCA2
mutations among high risk breast cancer patients in Jordan. BMC Cancer
18(1):152, 2018. PMID: 29409476.
36. Webster RD, Ross JL, Arun BK. The changing landscape of hereditary cancer
genetic testing. Cancer 124(4):664-6, 2018. e-Pub 2017. PMID: 29266190.
37. Gutierrez Barrera AM, Fouad TM, Song J, Webster R, Elsayegh N, Wood AL,
Demir A, Litton JK, Ueno NT, Arun BK. BRCA mutations in women with
inflammatory breast cancer. Cancer 124(3):466-474, 2018. e-Pub 2017. PMID:
29044548.
38. Chaoul A, Milbury K, Spelman A, Basen-Engquist K, Hall MH, Wei Q, Shih YT,
Arun B, Valero V, Perkins GH, Babiera GV, Wangyal T, Engle R, Harrison CA,
Li Y, Cohen L. Randomized trial of Tibetan yoga in patients with breast
cancer undergoing chemotherapy. Cancer Cytopathol 124(1):36-45, 2018.
e-Pub 2017. PMID: 28940301.
39. Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada
BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson
A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A feasibility study of
neoadjuvant talazoparib for operable breast cancer patients with a
germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer
3:49, 2017. PMID: 29238749.
40. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A,
Soucy P, Glubb D, Rostamianfar A, Bolla MK, Wang Q, Tyrer J, Dicks E, Lee
A, Wang Z, Allen J, Keeman R, Eilber U, French JD, Qing Chen X, Fachal L,
McCue K, McCart Reed AE, Ghoussaini M, Carroll JS, Jiang X, Finucane H,
Adams M, Adank MA, Ahsan H, Aittomäki K, Anton-Culver H, Antonenkova NN,
Arndt V, Aronson KJ, Arun B, Auer PL, Bacot F, Barrdahl M, Baynes C,
Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C,
Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brand JS, Brauch H,
Brennan P, Brenner H, Brinton L, Broberg P, Brock IW, Broeks A,
Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Butterbach K, Cai Q,
Cai H, Caldés T, Canzian F, Carracedo A, Carter BD, Castelao JE, Chan TL,
David Cheng TY, Seng Chia K, Choi JY, Christiansen H, Clarke CL, NBCS
Collaborators, Collée M, Conroy DM, Cordina-Duverger E, Cornelissen S, Cox
DG, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Devilee P, Doheny
KF, Dörk T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM,
Ekici AB, Eliassen AH, Ellberg C, Elvira M, Engel C, Eriksson M, Fasching
PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fritschi L,
Gaborieau V, Gabrielson M, Gago-Dominguez M, Gao YT, Gapstur SM,
García-Sáenz JA, Gaudet MM, Georgoulias V, Giles GG, Glendon G, Goldberg
MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J,
Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hamann
U, Hamel N, Hankinson S, Harrington P, Hart SN, Hartikainen JM, Hartman M,
Hein A, Heyworth J, Hicks B, Hillemanns P, Ho DN, Hollestelle A, Hooning
MJ, Hoover RN, Hopper JL, Hou MF, Hsiung CN, Huang G, Humphreys K,
Ishiguro J, Ito H, Iwasaki M, Iwata H, Jakubowska A, Janni W, John EM,
Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M,
Kaczmarek K, Kang D, Kasuga Y, Kerin MJ, Khan S, Khusnutdinova E, Kiiski
JI, Kim SW, Knight JA, Kosma VM, . . .Easton DF. Association analysis
identifies 65 new breast cancer risk loci. Nature 551(7678):92-94, 2017.
e-Pub 2017. PMID: 29059683.
41. Schvartsman G, Gutierrez-Barrera AM, Song J, Ueno NT, Peterson SK, Arun B.
Association between weight gain during adjuvant chemotherapy for
early-stage breast cancer and survival outcomes. Cancer Med
6(11):2515-2522, 2017. e-Pub 2017. PMID: 29024537.
42. Wang X, Yao J, Wang J, Zhang Q, Brady SW, Arun B, Seewaldt VL, Yu D.
Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast
Cancer Prevention. Cancer Prev Res (Phila) 10(11):641-650, 2017. e-Pub
2017. PMID: 28877935.
43. Somlo G, Frankel P, Arun B, Ma CX, Garcia A, Cigler T, Cream L, Harvey H,
Sparano JA, Nanda R, Chew HK, Moynihan T, Goetz MP, Vahdat L, Beumer JH,
Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR,
Ferry-Galow K, Chen A, Ruel C, Newman E, Gandara DR, Weitzel JN. Efficacy
of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in
Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast
Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res
23(15):4066-4076, 2017. e-Pub 2017. PMID: 28356425.
44. Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y,
Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton JK, Arun B, Hortobagyi
GN, Hung MC. PARP inhibitor upregulates PD-L1 expression and enhances
cancer-associated immunosuppression. Clin Cancer Res 23(14):3711-3720,
2017. e-Pub 2017. PMID: 28167507.
45. Milbury K, Kavanagh A, Meng Z, Chen Z, Chandwani KD, Garcia K, Perkins GH,
McQuade J, Raghuram NV, Nagarathna R, Liao Z, Nagendra HR, Chen J, Guo X,
Liu L, Arun B, Cohen L. Depressive symptoms and positive affect in Chinese
and United States breast cancer survivors: a cross-cultural comparison.
Support Care Cancer 25(7):2103-210, 2017. e-Pub 2017. PMID: 28233122.
46. Han CH, Lu J, Wei Q, Bondy ML, Brewster AM, Yu TK, Buchholz TA, Arun BK,
Wang LE. The functional promoter polymorphism (-842G>C) in the PIN1 gene
is associated with decreased risk of breast cancer in non-Hispanic white
women 55 years and younger. Breast Cancer Res Treat 122(1):243-9, 2017.
e-Pub 2009. PMID: 20033770.
47. Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H,
Lim B, Mellas N, Ueno NT, Fouad TM. Novel therapeutic strategies in the
treatment of triple-negative breast cancer. Ther Adv Med Oncol
9(7):493-511, 2017. e-Pub 2017. PMID: 28717401.
48. Raghavendra A, Sinha AK, Le-Petross HT, Garg N, Hsu L, Patangan M, Bevers
TB, Shen Y, Banu A, Tripathy D, Bedrosian I, Barcenas CH. Mammographic
breast density is associated with the development of contralateral breast
cancer. Cancer 123(11):1935-1940, 2017. e-Pub 2017. PMID: 28135395.
49. Cropper C, Woodson A, Arun B, Barcenas C, Litton J, Noblin S, Liu D, Park
M, Daniels M. Evaluating the NCCN Clinical Criteria for Recommending BRCA1
and BRCA2 Genetic Testing in Patients With Breast Cancer. J Natl Compr
Canc Netw 15(6):797-803, 2017. PMID: 28596260.
50. Parkes A, Arun BK, Litton JK. Systemic Treatment Strategies for Patients
with Hereditary Breast Cancer Syndromes. Oncologist 22(6):655-666, 2017.
e-Pub 2017. PMID: 28469042.
51. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ,
Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC, Lee JM,
Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D,
Lecarpentier J, Leslie G, Aalfs CM, Aben KKH, Adams M, Adlard J, Andrulis
IL, Anton-Culver H, Antonenkova N, AOCS study group, Aravantinos G, Arnold
N, Arun BK, Arver B, Azzollini J, Balmaña J, Banerjee SN, Barjhoux L,
Barkardottir RB, Bean Y, Beckmann MW, Beeghly-Fadiel A, Benitez J,
Bermisheva M, Bernardini MQ, Birrer MJ, Bjorge L, Black A, Blankstein K,
Blok MJ, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Borg Å, Bradbury
AR, Brenton JD, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma
F, Brunet J, Buecher B, Butzow R, Buys SS, Caldes T, Caligo MA, Campbell
I, Cannioto R, Carney ME, Cescon T, Chan SB, Chang-Claude J, Chanock S,
Chen XQ, Chiew YE, Chiquette J, Chung WK, Claes KBM, Conner T, Cook LS,
Cook J, Cramer DW, Cunningham JM, D'Aloisio AA, Daly MB, Damiola F,
Damirovna SD, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A,
Delnatte C, Doheny KF, Diez O, Ding YC, Doherty JA, Domchek SM, Dorfling
CM, Dörk T, Dossus L, Duran M, Dürst M, Dworniczak B, Eccles D, Edwards T,
Eeles R, Eilber U, Ejlertsen B, Ekici AB, Ellis S, Elvira M, EMBRACE
Study, Eng KH, Engel C, Evans DG, Fasching PA, Ferguson S, Ferrer SF,
Flanagan JM, Fogarty ZC, Fortner RT, Fostira F, Foulkes WD, Fountzilas G,
Fridley BL, Friebel TM, Friedman E, Frost D, Ganz PA, Garber J, García MJ,
Garcia-Barberan V, Gehrig A, GEMO Study Collaborators, Gentry-Maharaj A,
Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goldgar DE,
Goranova T, Gore M, Greene MH, Gronwald J, Gruber S, Hahnen E, Haiman CA,
Håkansson N, Hamann U, Hansen TVO, Harrington PA, Harris HR, Hauke J,
HEBON Study, Hein A, Henderson A, Hildebrandt MAT, Hillemanns P, Hodgson
S, Høgdall CK, Høgdall E, Hogervorst FBL, Holland H, Hooning MJ, Hosking
K, Huang RY, Hulick PJ, Hung J, . . .Pharoah PDP. Identification of 12 new
susceptibility loci for different histotypes of epithelial ovarian cancer.
Nat Genet 49(5):680-691, 2017. e-Pub 2017. PMID: 28346442.
52. Fouad TM, Barrera AM, Reuben JM, Lucci A, Woodward WA, Stauder MC, Lim B,
DeSnyder SM, Arun B, Gildy B, Valero V, Hortobagyi GN, Ueno NT.
Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC
TNM staging system. Lancet Oncol 18(4):e228-e232, 2017. PMID: 28368261.
53. Arun B, Austin T, Babiera GV, Basen-Engquist K, Carmack CL, Chaoul A,
Cohen L, Connelly L, Haddad R, Harrison C, Li Y, Mallaiah S, Nagarathna R,
Parker PA, Perkins GH, Reuben JM, Shih YT, Spelman A, Sood A, Yang P,
Yeung SJ. A Comprehensive Lifestyle Randomized Clinical Trial: Design and
Initial Patient Experience. Integr Cancer Ther 16(1):3-20, 2017. e-Pub
2016. PMID: 27903842.
54. Bayraktar S, Arun B. BRCA mutation genetic testing implications in the
United States. Breast 31:224-232, 2017. e-Pub 2016. PMID: 27931006.
55. Hamdi Y, Soucy P, Kuchenbaeker KB, Pastinen T, Droit A, Lemaçon A, Adlard
J, Aittomäki K, Andrulis IL, Arason A, Arnold N, Arun BK, Azzollini J,
Bane A, Barjhoux L, Barrowdale D, Benitez J, Berthet P, Blok MJ, Bobolis
K, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS,
Caligo MA, Chiquette J, Chung WK, Claes KB, Daly MB, Damiola F, Davidson
R, De la Hoya M, De Leeneer K, Diez O, Ding YC, Dolcetti R, Domchek SM,
Dorfling CM, Eccles D, Eeles R, Einbeigi Z, Ejlertsen B, EMBRACE, Engel C,
Gareth Evans D, Feliubadalo L, Foretova L, Fostira F, Foulkes WD,
Fountzilas G, Friedman E, Frost D, Ganschow P, Ganz PA, Garber J, Gayther
SA, GEMO Study Collaborators, Gerdes AM, Glendon G, Godwin AK, Goldgar DE,
Greene MH, Gronwald J, Hahnen E, Hamann U, Hansen TV, Hart S, Hays JL,
HEBON, Hogervorst FB, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L,
Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Joseph V, Just W,
Kaczmarek K, Karlan BY, KConFab Investigators, Kets CM, Kirk J, Kriege M,
Laitman Y, Laurent M, Lazaro C, Leslie G, Lester J, Lesueur F, Liljegren
A, Loman N, Loud JT, Manoukian S, Mariani M, Mazoyer S, McGuffog L,
Meijers-Heijboer HE, Meindl A, Miller A, Montagna M, Mulligan AM,
Nathanson KL, Neuhausen SL, Nevanlinna H, Nussbaum RL, Olah E, Olopade OI,
Ong KR, Oosterwijk JC, Osorio A, Papi L, Park SK, Pedersen IS, Peissel B,
Segura PP, Peterlongo P, Phelan CM, Radice P, Rantala J,
Rappaport-Fuerhauser C, Rennert G, Richardson A, Robson M, Rodriguez GC,
Rookus MA, Schmutzler RK, Sevenet N, Shah PD, Singer CF, Slavin TP, Snape
K, Sokolowska J, Sønderstrup IM, Southey M, Spurdle AB, Stadler Z,
Stoppa-Lyonnet D, Sukiennicki G, Sutter C, Tan Y, Tea MK, Teixeira MR,
Teulé A, Teo SH, Terry MB, Thomassen M, Tihomirova L, Tischkowitz M,
Tognazzo S, Toland AE, Tung N, van den Ouweland AM, van der Luijt RB, van
Engelen K, van Rensburg EJ, Varon-Mateeva R, Wappenschmidt B, Wijnen JT,
Rebbeck T, Chenevix-Trench G, Offit K, Couch FJ, Nord S, . . Simard J.
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers
with genetic variants showing differential allelic expression:
identification of a modifier of breast cancer risk at locus 11q22.3.
Breast Cancer Res Treat 161(1):117-134, 2017. e-Pub 2016. PMID: 27796716.
56. Fernandes GC, Michelli RA, Galvão HC, Paula AE, Pereira R, Andrade CE,
Felicio PS, Souza CP, Mendes DR, Volc S, Berardinelli GN, Grasel RS,
Sabato CS, Viana DV, Mauad EC, Scapulatempo-Neto C, Arun B, Reis RM,
Palmero EI. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population
sample at-risk for hereditary breast cancer and characterization of its
genetic ancestry. Oncotarget 7(49):80465-80481, 2016. PMID: 27741520.
57. Rebbeck TR, Friebel TM, Mitra N, Wan F, Chen S, Andrulis IL, Apostolou P,
Arnold N, Arun BK, Barrowdale D, Benitez J, Berger R, Berthet P, Borg A,
Buys SS, Caldes T, Carter J, Chiquette J, Claes KB, Couch FJ, Cybulski C,
Daly MB, de la Hoya M, Diez O, Domchek SM, Nathanson KL, Durda K, Ellis S,
EMBRACE, Evans DG, Foretova L, Friedman E, Frost D, Ganz PA, Garber J,
Glendon G, Godwin AK, Greene MH, Gronwald J, Hahnen E, Hallberg E, Hamann
U, Hansen TV, HEBON, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R,
Jaworska-Bieniek K, John EM, Karlan BY, Kaufman B, Investigators K, Kwong
A, Laitman Y, Lasset C, Lazaro C, Lester J, Loman N, Lubinski J, Manoukian
S, Mitchell G, Montagna M, Neuhausen SL, Nevanlinna H, Niederacher D,
Nussbaum RL, Offit K, Olah E, Olopade OI, Park SK, Piedmonte M, Radice P,
Rappaport-Fuerhauser C, Rookus MA, Seynaeve C, Simard J, Singer CF, Soucy
P, Southey M, Stoppa-Lyonnet D, Sukiennicki G, Szabo CI, Tancredi M,
Teixeira MR, Teo SH, Terry MB, Thomassen M, Tihomirova L, Tischkowitz M,
Toland AE, Toloczko-Grabarek A, Tung N, van Rensburg EJ, Villano D,
Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Zidan J, Zorn KK, McGuffog L,
Easton D, Chenevix-Trench G, Antoniou AC, Ramus SJ. Inheritance of
deleterious mutations at both BRCA1 and BRCA2 in an international sample
of 32,295 women. Breast Cancer Res 18(1):112, 2016. PMID: 27836010.
58. Lu Q, You J, Kavanagh A, Warmoth K, Meng Z, Chen Z, Chandwani KD, Perkins
GH, McQuade JL, Raghuram NV, Nagarathna R, Liao Z, Nagendra HR, Chen J,
Guo X, Liu L, Arun B, Cohen L. Differences in quality of life between
American and Chinese breast cancer survivors. Support Care Cancer
24(9):3775-82, 2016. e-Pub 2016. PMID: 27048455.
59. Lawrenson K, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J,
Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomäki K, Andrulis IL,
Anton-Culver H, Arndt V, Arun BK, Arver B, Bandera EV, Barile M,
Barkardottir RB, Barrowdale D, Beckmann MW, Benitez J, Berchuck A, Bisogna
M, Bjorge L, Blomqvist C, Blot W, Bogdanova N, Bojesen A, Bojesen SE,
Bolla MK, Bonanni B, Børresen-Dale AL, Brauch H, Brennan P, Brenner H,
Bruinsma F, Brunet J, Buhari SA, Burwinkel B, Butzow R, Buys SS, Cai Q,
Caldes T, Campbell I, Canniotto R, Chang-Claude J, Chiquette J, Choi JY,
Claes KB, GEMO Study Collaborators, Cook LS, Cox A, Cramer DW, Cross SS,
Cybulski C, Czene K, Daly MB, Damiola F, Dansonka-Mieszkowska A, Darabi H,
Dennis J, Devilee P, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T,
Dumont M, Ehrencrona H, Ejlertsen B, Ellis S, EMBRACE, Engel C, Lee E,
Evans DG, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher
O, Flyger H, Foretova L, Fostira F, Foulkes WD, Fridley BL, Friedman E,
Frost D, Gambino G, Ganz PA, Garber J, García-Closas M, Gentry-Maharaj A,
Ghoussaini M, Giles GG, Glasspool R, Godwin AK, Goldberg MS, Goldgar DE,
González-Neira A, Goode EL, Goodman MT, Greene MH, Gronwald J, Guénel P,
Haiman CA, Hall P, Hallberg E, Hamann U, Hansen TV, Harrington PA, Hartman
M, Hassan N, Healey S, Hereditary Breast and Ovarian Cancer Research Group
Netherlands (HEBON), Heitz F, Herzog J, Høgdall E, Høgdall CK, Hogervorst
FB, Hollestelle A, Hopper JL, Hulick PJ, Huzarski T, Imyanitov EN, KConFab
Investigators, Australian Ovarian Cancer Study Group, Isaacs C, Ito H,
Jakubowska A, Janavicius R, Jensen A, John EM, Johnson N, Kabisch M, Kang
D, Kapuscinski M, Karlan BY, Khan S, Kiemeney LA, Kjaer SK, Knight JA,
Konstantopoulou I, Kosma VM, Kristensen V, Kupryjanczyk J, Kwong A, de la
Hoya M, Laitman Y, Lambrechts D, Le N, De Leeneer K, Lester J, Levine DA,
Li J, Lindblom A, Long J, Lophatananon A, Loud JT, Lu K, Lubinski J,
Mannermaa A, . . .Gayther SA. Functional mechanisms underlying pleiotropic
risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Nat Commun 7:12675, 2016. PMID: 27601076.
60. Kehl KL, Shen C, Litton JK, Arun B, Giordano SH. Erratum to: Rates of
BRCA1/2 mutation testing among young survivors of breast cancer. Breast
Cancer Res Treat 159(1):201, 2016. PMID: 27464794.
61. Streff H, Profato J, Ye Y, Nebgen D, Peterson SK, Singletary C, Arun BK,
Litton JK. Cancer Incidence in First- and Second-Degree Relatives of BRCA1
and BRCA2 Mutation Carriers. Oncologist 21(7):869-74, 2016. e-Pub 2016.
PMID: 27306910.
62. Vigorito E, Kuchenbaecker KB, Beesley J, Adlard J, Agnarsson BA, Andrulis
IL, Arun BK, Barjhoux L, Belotti M, Benitez J, Berger A, Bojesen A,
Bonanni B, Brewer C, Caldes T, Caligo MA, Campbell I, Chan SB, Claes KB,
Cohn DE, Cook J, Daly MB, Damiola F, Davidson R, Pauw Ad, Delnatte C, Diez
O, Domchek SM, Dumont M, Durda K, Dworniczak B, Easton DF, Eccles D,
Edwinsdotter Ardnor C, Eeles R, Ejlertsen B, Ellis S, Evans DG,
Feliubadalo L, Fostira F, Foulkes WD, Friedman E, Frost D, Gaddam P, Ganz
PA, Garber J, Garcia-Barberan V, Gauthier-Villars M, Gehrig A, Gerdes AM,
Giraud S, Godwin AK, Goldgar DE, Hake CR, Hansen TV, Healey S, Hodgson S,
Hogervorst FB, Houdayer C, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L,
Izquierdo A, Jacobs L, Jakubowska A, Janavicius R, Jaworska-Bieniek K,
Jensen UB, John EM, Vijai J, Karlan BY, Kast K, Investigators K, Khan S,
Kwong A, Laitman Y, Lester J, Lesueur F, Liljegren A, Lubinski J, Mai PL,
Manoukian S, Mazoyer S, Meindl A, Mensenkamp AR, Montagna M, Nathanson KL,
Neuhausen SL, Nevanlinna H, Niederacher D, Olah E, Olopade OI, Ong KR,
Osorio A, Park SK, Paulsson-Karlsson Y, Pedersen IS, Peissel B, Peterlongo
P, Pfeiler G, Phelan CM, Piedmonte M, Poppe B, Pujana MA, Radice P,
Rennert G, Rodriguez GC, Rookus MA, Ross EA, Schmutzler RK, Simard J,
Singer CF, Slavin TP, Soucy P, Southey M, Steinemann D, Stoppa-Lyonnet D,
Sukiennicki G, Sutter C, Szabo CI, Tea MK, Teixeira MR, Teo SH, Terry MB,
Thomassen M, Tibiletti MG, Tihomirova L, Tognazzo S, van Rensburg EJ,
Varesco L, Varon-Mateeva R, Vratimos A, Weitzel JN, McGuffog L, Kirk J,
Toland AE, Hamann U, Lindor N, Ramus SJ, Greene MH, Couch FJ, Offit K,
Pharoah PD, Chenevix-Trench G, Antoniou AC. Fine-Scale Mapping at 9p22.2
Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in
BRCA1 and BRCA2 Mutation Carriers. PLoS One 11(7):e0158801, 2016. PMID:
27463617.
63. Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J,
Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM,
Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N.
Phase I biomarker modulation study of atorvastatin in women at increased
risk for breast cancer. Breast Cancer Res Treat 158(1):67-77, 2016. e-Pub
2016. PMID: 27287781.
64. Madorsky-Feldman D, Sklair-Levy M, Perri T, Laitman Y, Paluch-Shimon S,
Schmutzler R, Rhiem K, Lester J, Karlan BY, Singer CF, Van Maerken T,
Claes K, Brunet J, Izquierdo A, Teulé A, Lee JW, Kim SW, Arun B,
Jakubowska A, Lubinski J, Tucker K, Poplawski NK, Varesco L, Bonelli LA,
Buys SS, Mitchell G, Tischkowitz M, Gerdes AM, Seynaeve C, Robson M, Kwong
A, Tung N, Tessa N, Domchek SM, Godwin AK, Rantala J, Arver B, Friedman E.
An international survey of surveillance schemes for unaffected BRCA1 and
BRCA2 mutation carriers. Breast Cancer Res Treat 157(2):319-27, 2016.
e-Pub 2016. PMID: 27117159.
65. Zeng C, Guo X, Long J, Kuchenbaecker KB, Droit A, Michailidou K,
Ghoussaini M, Kar S, Freeman A, Hopper JL, Milne RL, Bolla MK, Wang Q,
Dennis J, Agata S, Ahmed S, Aittomäki K, Andrulis IL, Anton-Culver H,
Antonenkova NN, Arason A, Arndt V, Arun BK, Arver B, Bacot F, Barrowdale
D, Baynes C, Beeghly-Fadiel A, Benitez J, Bermisheva M, Blomqvist C, Blot
WJ, Bogdanova NV, Bojesen SE, Bonanni B, Borresen-Dale AL, Brand JS,
Brauch H, Brennan P, Brenner H, Broeks A, Brüning T, Burwinkel B, Buys SS,
Cai Q, Caldes T, Campbell I, Carpenter J, Chang-Claude J, Choi JY, Claes
KB, Clarke C, Cox A, Cross SS, Czene K, Daly MB, de la Hoya M, De Leeneer
K, Devilee P, Diez O, Domchek SM, Doody M, Dorfling CM, Dörk T,
Dos-Santos-Silva I, Dumont M, Dwek M, Dworniczak B, Egan K, Eilber U,
Einbeigi Z, Ejlertsen B, Ellis S, Frost D, Lalloo F, EMBRACE, Fasching PA,
Figueroa J, Flyger H, Friedlander M, Friedman E, Gambino G, Gao YT, Garber
J, García-Closas M, Gehrig A, Damiola F, Lesueur F, Mazoyer S,
Stoppa-Lyonnet D, behalf of GEMO Study Collaborators, Giles GG, Godwin AK,
Goldgar DE, González-Neira A, Greene MH, Guénel P, Haeberle L, Haiman CA,
Hallberg E, Hamann U, Hansen TV, Hart S, Hartikainen JM, Hartman M, Hassan
N, Healey S, Hogervorst FB, Verhoef S, HEBON, Hendricks CB, Hillemanns P,
Hollestelle A, Hulick PJ, Hunter DJ, Imyanitov EN, Isaacs C, Ito H,
Jakubowska A, Janavicius R, Jaworska-Bieniek K, Jensen UB, John EM, Joly
Beauparlant C, Jones M, Kabisch M, Kang D, Karlan BY, Kauppila S, Kerin
MJ, Khan S, Khusnutdinova E, Knight JA, Konstantopoulou I, Kraft P, Kwong
A, Laitman Y, Lambrechts D, Lazaro C, Le Marchand L, Lee CN, Lee MH,
Lester J, Li J, Liljegren A, Lindblom A, Lophatananon A, Lubinski J, Mai
PL, Mannermaa A, Manoukian S, Margolin S, Marme F, Matsuo K, McGuffog L,
Meindl A, Menegaux F, Montagna M, Muir K, Mulligan AM, Nathanson KL,
Neuhausen SL, Nevanlinna H, Newcomb PA, Nord S, Nussbaum RL, Offit K, Olah
E, Olopade OI, Olswold C, Osorio A, Papi L, . . .Zheng W. Identification
of independent association signals and putative functional variants for
breast cancer risk through fine-scale mapping of the 12p11 locus. Breast
Cancer Res 18(1):64, 2016. PMID: 27459855.
66. Ovarian Cancer Association Consortium, Breast Cancer Association
Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A,
van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki
K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC,
Apicella C, Arndt V, Arnold N, Arun BK,......... No clinical utility of
KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol
141(2):386-401, 2016. e-Pub 2015. PMID: 25940428.
67. Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AM, Strong L, Shaw
K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK9,
Aytac U2, Routbort M10, Subbiah V11, Janku F11, Davies MA12, Kopetz S13,
Mendelsohn J14, Mills GB, Chen K. Incidental germline variants in 1000
advanced cancers on a prospective somatic genomic profiling protocol. Ann
Oncol 27(5):795-800, 2016. e-Pub 2016. PMID: 26787237.
68. Acharya S1, Xu J, Wang X, Jain S, Wang H, Zhang Q, Chang CC, Bower J, Arun
B, Seewaldt V, Yu D. Downregulation of GLUT4 contributes to effective
intervention of estrogen receptor-negative/HER2-overexpressing early stage
breast disease progression by lapatinib. Am J Cancer Res 6(5):981-95,
2016. PMID: 27293993.
69. Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD,
Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, Dicks E,
Barrowdale D, Sinnott-Armstrong NA, Sallari RC, Hillman KM, Kaufmann S,
Sivakumaran H, Moradi Marjaneh M, Lee JS, Hills M, Jarosz M, Drury S,
Canisius S, Bolla MK, Dennis J, Wang Q, Hopper JL, Southey MC, Broeks A,
Schmidt MK, Lophatananon A, Muir K, Beckmann MW, Fasching PA,
Dos-Santos-Silva I, Peto J, Sawyer EJ, Tomlinson I, Burwinkel B, Marme F,
Guénel P, Truong T, Bojesen SE, Flyger H, González-Neira A, Perez JI,
Anton-Culver H, Eunjung L, Arndt V, Brenner H, Meindl A, Schmutzler RK,
Brauch H, Hamann U, Aittomäki K, Blomqvist C, Ito H, Matsuo K, Bogdanova
N, Dörk T, Lindblom A, Margolin S, Kosma VM, Mannermaa A, Tseng CC, Wu AH,
Lambrechts D, Wildiers H, Chang-Claude J, Rudolph A, Peterlongo P, Radice
P, Olson JE, Giles GG, Milne RL, Haiman CA, Henderson BE, Goldberg MS, Teo
SH, Yip CH, Nord S, Borresen-Dale AL, Kristensen V, Long J, Zheng W,
Pylkäs K, Winqvist R, Andrulis IL, Knight JA, Devilee P, Seynaeve C,
Figueroa J, Sherman ME, Czene K, Darabi H, Hollestelle A, van den Ouweland
AM, Humphreys K, Gao YT, Shu XO, Cox A, Cross SS, Blot W, Cai Q,
Ghoussaini M, Perkins B, Shah M, Choi JY, Kang D, Lee SC, Hartman M,
Kabisch M, Torres D, Jakubowska A, Lubinski J, Brennan P, Sangrajrang S,
Ambrosone CB, Toland AE, Shen CY, Wu PE, Orr N, Swerdlow A, McGuffog L,
Healey S, Lee A, Kapuscinski M, John EM, Terry MB, Daly MB, Goldgar DE,
Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ,
Neuhausen SL, Ejlertsen B, . . .Arun BK, . . .Edwards SL. Breast cancer
risk variants at 6q25 display different phenotype associations and
regulate ESR1, RMND1 and CCDC170. Nat Genet 48(4):374-86, 2016. e-Pub
2016. PMID: 26928228.
70. Couch FJ, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S,
Lilyquist J, Olswold C, Hallberg E, Agata S, Ahsan H, Aittomäki K,
Ambrosone C, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B,
Barile M, Barkardottir RB, Barrowdale D, Beckmann L, Beckmann MW, Benitez
J, Blank SV, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B,
Brauch H, Brenner H, Burwinkel B, Buys SS, Caldes T, Caligo MA, Canzian F,
Carpenter J, Chang-Claude J, Chanock SJ, Chung WK, Claes KB, Cox A, Cross
SS, Cunningham JM, Czene K, Daly MB, Damiola F, Darabi H, de la Hoya M,
Devilee P, Diez O, Ding YC, Dolcetti R, Domchek SM, Dorfling CM,
Dos-Santos-Silva I, Dumont M, Dunning AM, Eccles DM, Ehrencrona H, Ekici
AB, Eliassen H, Ellis S, Fasching PA, Figueroa J, Flesch-Janys D, Försti
A, Fostira F, Foulkes WD, Friebel T, Friedman E, Frost D, Gabrielson M,
Gammon MD, Ganz PA, Gapstur SM, Garber J, Gaudet MM, Gayther SA, Gerdes
AM, Ghoussaini M, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE,
González-Neira A, Greene MH, Gronwald J, Guénel P, Gunter M, Haeberle L,
Haiman CA, Hamann U, Hansen TV, Hart S, Healey S, Heikkinen T, Henderson
BE, Herzog J, Hogervorst FB, Hollestelle A, Hooning MJ, Hoover RN, Hopper
JL, Humphreys K, Hunter DJ, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska
A, James P, Janavicius R, Jensen UB, John EM, Jones M, Kabisch M, Kar S,
Karlan BY, Khan S, Khaw KT, Kibriya MG, Knight JA, Ko YD, Konstantopoulou
I, Kosma VM, Kristensen V, Kwong A, Laitman Y, Lambrechts D, Lazaro C, Lee
E, Le Marchand L, Lester J, Lindblom A, Lindor N, Lindstrom S, Liu J, Long
J, Lubinski J, Mai PL, Makalic E, Malone KE, Mannermaa A, Manoukian S,
Margolin S, Marme F, Martens JW, McGuffog L, Meindl A, Miller A, Milne RL,
Miron P, Montagna M, Mazoyer S, Mulligan AM, Muranen TA, Nathanson KL,
Neuhausen SL, Nevanlinna H, Nordestgaard BG, Nussbaum RL, Offit K, Olah E,
Olopade OI, Olson JE, Osorio A, Park SK, Peeters PH, Peissel B, Peterlongo
P, Peto J, . . .Antoniou AC. Identification of four novel susceptibility
loci for oestrogen receptor negative breast cancer. Nat Commun(7):11375,
2016. PMID: 27117709.
71. Elsayegh N, Barrera AM, Muse KI, Lin H, Kuerer HM, Helm M, Litton JK, Arun
BK. Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal
Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing. Front Genet
7:71, 2016. PMID: 27200080.
72. Biswas S, Atienza P, Chipman J, Blackford AL, Arun B, Hughes K, Parmigiani
G. A two-stage approach to genetic risk assessment in primary care. Breast
Cancer Res Treat 155(2):375-83, 2016. e-Pub 2016. PMID: 26786860.
73. Kehl KL, Shen C, Litton JK, Arun B, Giordano SH. Rates of BRCA1/2 mutation
testing among young survivors of breast cancer. Breast Cancer Res Treat
155(1):165-73, 2016. e-Pub 2015. PMID: 26706041.
74. Kehl KL, Shen C, Litton JK, Arun B, Giordano SH. Rates of BRCA1/2 mutation
testing among young survivors of breast cancer. Breast Cancer Res Treat
155(1):165-73, 2016. PMID: 26706041.
75. Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, Lipkin SM,
Syngal S, Wollins DS, Lindor NM. American Society of Clinical Oncology
Policy Statement Update: Genetic and Genomic Testing for Cancer
Susceptibility. J Clin Oncol 33(31):3660-7, 2015. e-Pub 2015. PMID:
26324357.
76. Jain S, Wang X, Chang CC, Ibarra-Drendall C, Wang H, Zhang Q, Brady SW, Li
P, Zhao H, Dobbs J, Kyrish M, Tkaczyk TS, Ambrose A, Sistrunk C, Arun BK,
Richards-Kortum R, Jia W, Seewaldt VL, Yu D. Src inhibition blocks c-Myc
translation and glucose metabolism to prevent the development of breast
cancer. Cancer Res 75(22):4863-75, 2015. e-Pub 2015. PMID: 26383165.
77. Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK,
Bedrosian I, Albarracin CT, Valero V, Arun B. High incidence of germline
BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu
negative tumors. Cancer 121(19):3422-7, 2015. e-Pub 2015. PMID: 26280679.
78. Litton JK, Lee JH, Arun BK. Reply to BRCA2-associated pancreatic cancer
and current screening guidelines. Cancer 121(17):3047, 2015. e-Pub 2015.
PMID: 26018033.
79. Woodson AH, Profato JL, Rizvi SH, Elsayegh N, Rieber AG, Arun BK. Service
delivery model and experiences in a cancer genetics clinic for an
underserved population. J Health Care Poor Underserved 26(3):784-91, 2015.
PMID: 26320913.
80. Bayraktar S, Qiu H, Liu D, Shen Y, Gutierrez-Barrera AM, Arun BK, Sahin
AA. Histopathological features of non-neoplastic breast parenchyma do not
predict BRCA mutation status of patients with invasive breast cancer.
Biomark Cancer 7(7):39-49, 2015. PMID: 26327783.
81. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA,
Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera
G, Buchholz TA, Valero V, Ueno NT. Overall survival differences between
patients with inflammatory and noninflammatory breast cancer presenting
with distant metastasis at diagnosis. Breast Cancer Res Treat
152(2):407-16, 2015. e-Pub 2015. PMID: 26017070.
82. Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE,
Gemignani MLO, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras
H, Kumar S, Kuruan A, Laronga C,Layman RN, Seewaldt V, Specht MC,
Visvanathan K, Wallace A, Bergman MA, Kumar R. Breast Cancer Risk
Reduction, Version 2.2015. J Natl Compr Canc Netw 13(7):880-915, 2015.
PMID: 26150582.
83. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA,
Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera
G, Buchholz TA, Valero V, Ueno NT. Erratum to: Overall survival
differences between patients with inflammatory and noninflammatory breast
cancer presenting with distant metastasis at diagnosis. Breast Cancer Res
Treat 152(2):417, 2015. PMID: 26092296.
84. Arun B, Akar U, Gutierrez-Barrera AM, Hortobagyi GN, Ozpolat B. The PARP
inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and
BRCA2 mutant breast cancer cells. Intl J Oncol 47(1):262-8, 2015. e-Pub
2015. PMID: 25975349.
85. Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C,
McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM,
Wang A, Lippman SM, Hershman DL. Effects of a green tea extract,
Polyphenon E, on systemic biomarkers of growth factor signalling in women
with hormone receptor-negative breast cancer. J Hum Nutr Diet
28(3):272-82, 2015. e-Pub 2014. PMID: 24646362.
86. Mitri ZI, Jackson M, Garby C, Song J, Giordano SH, Hortobagyi GN,
Singletary CN, Hasmi SS, Arun BK, Litton JK. BRCAPRO 6.0 Model Validation
in male patients presenting for BRCA testing. Oncologist 20(6):593-7,
2015. e-Pub 2015. PMID: 25948675.
87. Bayraktar S, Gutierrez Barrera AM, Arun B, Jackson MA. Genotype-phenotype
correlations by ethnicity and mutation location in BRCA mutation carriers.
Breast J 21(3):260-7, 2015. e-Pub 2015. PMID: 25789811.
88. Elsayegh N, Profato J, Barrera AM, Lin H, Kuerer HM, Ardic C, Litton JK,
Tripathy D, Arun BK. Predictors that influence election of contralateral
prophylactic mastectomy among women with ductal carcinoma in situ who are
BRCA-negative. J Cancer 6(7):610-5, 2015. PMID: 26078790.
89. Guan X, Liu H, Ju J, Li Y, Li P, Wang LE, Brewster AM, Buchholz TA, Arun
BK, Wei Q, Liu Z. Genetic variant rs16430 6bp > 0bp at the
microRNA-binding site in TYMS and risk of sporadic breast cancer risk in
non-Hispanic white women aged ≤ 55 years. Mol Carcinog 54(4):281-90, 2015.
e-Pub 2013. PMID: 24166930.
90. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer
S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL; CIMBA
Consortium, Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J,
Friedman E, Ehrencrona H, Stenmark-Askmalm M, Einbeigi Z, Loman N, Harbst
K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL,
Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK...... Association of
type and location of BRCA1 and BRCA2 mutations with risk of breast and
ovarian cancer. JAMA 313(13):1347-61, 2015. PMID: 25849179.
91. Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A,
Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys
SS; BCFR, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg
EJ, Neuhausen SL, Ding YC, Gerdes AM, Ejlertsen B, Nielsen FC, Hansen TV,
Osorio A, Benitez J, Andrés-Conejero R, Segota E, Weitzel JN, Thelander M,
Peterlongo P, Radice P, Pensotti V, Dolcetti R, Bonanni B, Peissel B,
Zaffaroni D, Scuvera G, Manoukian S, Varesco L, Capone GL, Papi L, Ottini
L, Yannoukakos D, Konstantopoulou I, Garber J, Hamann U, Donaldson A,
Brady A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, Douglas F, Cook J,
Arun BK, ……. An original phylogenetic approach identified mitochondrial
haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2
mutation carriers. Breast Cancer Res 17:61, 2015. PMID: 25925750.
92. Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, de Garibay GR,
Librado P, Sánchez-Gracia A, Rozas J, Bonifaci N, McGuffog L, Pankratz VS,
Islam A, Mateo F, Berenguer A, Petit A, Català I, Brunet J, Feliubadaló L,
Tornero E, Benítez J, Osorio A, Cajal TR, Nevanlinna H, Aittomäki K, Arun
BK,…. Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional
module and breast cancer risk in BRCA1/2 mutation carriers. PLoS One
10(4):e0120020. doi:10.1371, 2015. PMID: 25830658.
93. Profato JL, Arun B. Genetic risk assessment for breast and gynecological
malignancies. Curr Opin Obstet Gynecol 27(1):1-5, 2015. PMID: 25502427.
94. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson
K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y,
Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE,
Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding
YC, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, Barrowdale D, Dennis J,
Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P,
Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice
P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Arun B, ........
Identification of six new susceptibility loci for invasive epithelial
ovarian cancer. Nat Genet 47(2):164-71, 2015. e-Pub 2015. PMID: 25581431.
95. Rich TA, Woodson AH, Litton J, Arun B. Hereditary breast cancer syndromes
and genetic testing. J Surg Oncol 111(1):66-80, 2015. e-Pub 2014. PMID:
25381882.
96. Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard
J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA,
Schmidt MK, van der Baan FH, Spurdle AB, Walker LC, Lose F, Maia AT,
Montagna M, Matricardi L, Lubinski J, Jakubowska A, Gomez-Garcia EB,
Olopade Ol, Nussbaum RL, Nathanson KL, Domchek SM, Rebbeck TR, Arun
BK,.... Candidate genetic modifiers for breast and ovarian cancer risk in
BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev
24(1):308-16, 2015. e-Pub 2014. PMID: 25336561.
97. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun
BK, Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other
than breast and ovarian. Cancer 121(2):269-75, 2015. e-Pub 2014. PMID:
25224030.
98. Bayraktar S, Amendola L, Gutierrez-Barrera AM, Hashmi SS, Amos C, Gambello
M, Ready KJ, Arun B. Clinicopathologic characteristics of breast cancer in
BRCA-carriers and non-carriers in women 35 years of age or less. Breast
23(6):770-4, 2014. e-Pub 2014. PMID: 25231195.
99. Ratcliff CG, Lam CY, Arun B, Valero V, Cohen L. Ecological momentary
assessment of sleep, symptoms, and mood during chemotherapy for breast
cancer. Psychooncology 23(11):1220-8, 2014. e-Pub 2014. PMID: 24706506.
100. Elsayegh N, Kuerer HM, Lin H, Gutierrez-Barrera AM, Jackson M, Muse KI,
Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK. Predictors
that influence contralateral prophylactic mastectomy election among women
with ductal carcinoma in situ who were evaluated for BRCA genetic testing.
Ann Surg Oncol 21(11):3466-3472, 2014. e-Pub 2014. PMID: 24796968.
101. Woodson AH, Muse KI, Lin H, Jackson M, Mattair DN, Schover L, Woodard T,
McKenzie L, Theriault RL, Hortobagyi GN, Arun B, Petersen SK, Profato J,
Litton JK. Breast cancer, BRCA mutations, and attitudes regarding
pregnancy and preimplantation genetic diagnosis. Oncologist 19(8):797-804,
2014. e-Pub 2014. PMID: 24951607.
102. Rich TA, Liu M, Etzel CJ, Bannon SA, Mork ME, Ready K, Saraiya DS, Grubbs
EG, Perrier ND, Lu KH, Arun BK, Woodard TL, Schover LR, Litton JK.
Comparison of attitudes regarding preimplantation genetic diagnosis among
patients with hereditary cancer syndromes. Fam Cancer 13(2):291-9, 2014.
PMID: 24072553.
103. Biswas S, Arun B, Parmigiani G. Reclassification of predictions for
uncovering subgroup specific improvement. Stat Med 33(11):1914-27, 2014.
e-Pub 2013. PMID: 24353130.
104. Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T,
Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A,
Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE,
Kaklamani VG. Characteristics of individuals with breast cancer
rearrangements in BRCA1 and BRCA2. Cancer 120(10):1557-64, 2014. e-Pub
2014. PMID: 24522996.
105. Osorio A, Milne RL, Kuchenbaecker K, Vaclova T, Pita G, Alonso R,
Peterlongo P, Blanco I, de la Hoya M, Duran M, Diez O, Ramon Y, Cajal T,
Konstantopoulou I, Martinez-Bouzas C, Andres Conejero R, Soucy P, McGuffog
L, Barrowdate D, Lee A, Swe-Brca Arver B, Rantala J, Loman N, Ehrencrona
H, Olopade Ol, Beauttie MS, Domcheck SM, Nathanson K, Rebbeck TR, Arun
BK....., Karlan BY, Walsh C. DNA glycosylases involved in base excision
repair may be associated with cancer risk in BRCA1 and BRCA2 mutation
carriers. PLoS Genet 10(4):e1004256 doi: 10.137/journal.pgen.1004256,
2014. PMID: 24698998.
106. Chandwani K, Perkins G, Nagendra H, Raghurham NV, Spelman A, Nagarathna R,
Johnson K, Fortier A, Arun B, Wei Q, Kirschbaum C, Haddad R, Morris GS,
Scheetz J, Chaoul A, Cohen L. Randomized, controlled trial of yoga in
women with breast cancer undergoing radiotherapy. J Clin Oncol
32(10):1058-65, 2014. e-Pub 2014. PMID: 24590636.
107. Abdayem P, Ghosn M, Valero V, Walters R, Arun B, Murray JL, Theriault R,
Frye D, Ibrahim NK. Phase I and II study of gemcitabine and vinorelbine in
heavily pretreated patients with metastatic breast cancer and review of
the literature. J Cancer 5(5):351-9, 2014. PMID: 24723978.
108. Milbury K, Chaoul A, Biegler K, Wangyal T, Spelman A, Meyers CA, Arun B,
Palmer JL, Taylor J, Cohen L. Tibetan sound meditation for cognitive
dysfunction: results of a randomized controlled pilot trial.
Psychooncology 22(10):2354-63, 2013. e-Pub 2013. PMID: 23657969.
109. Cadiz F, Kuerer HM, Puga J, Camacho J, Cunill E, Arun B. Establishing a
program for individuals at high risk for breast cancer. J Cancer
4(5):433-446, 2013. PMID: 23833688.
110. Bayraktar S, Avery T, Altundag K, Broglio K, Arun BK. Association between
tumor characteristics and bone mineral density in postmenopausal breast
cancer patients. Breast J 19(4):431-434, 2013. e-Pub 2013. PMID: 23701522.
111. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK,
Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun
BK. Outcome of metastatic breast cancer in selected women with or without
deleterious BRCA mutations. Clin Exp Metastasis 30(5):631-642, 2013. e-Pub
2013. PMID: 23370825.
112. Biswas S, Atienza P, Chipman J, Hughes K, Gutierrez Barrera AM, Amos CI,
Arun B, Parmigiani G. Simplifying clinical use of the genetic risk
prediction model BRCAPRO. Breast Cancer Res Treat 139(2):571-579, 2013.
e-Pub 2013. PMID: 23690142.
113. Bojesen SE, Arun BK....., Campbell I, Mensenkamp AR, van Asperen CJ, van
Roozendaal KE, Meijers-Heijboer H, Collee JM, Oosterwijk JC, Hooning MJ,
Rookus MA, van der Luijt RB, Os TA, Evans DG, Frost D, Fineberg E, Barwell
J, Walker L, Kennedy MJ, Platte R, Davidson R, Ellis SD, Cole T,
Breasac-de Paillerets B, Buecher B, Damiola F, Faivre L, Frenay M,
Sinilnikova OM, Caron O, Giraud S, Mazoyer S, Bonadona V, Caux-Moncoutier
V, Toloczko-Grabarek A, Gronwald J, Byrski T, Spurdle AB, Bonanni B,
Zaffaroni D, Giannini G, Bernard L, Dolcetti R, Manoukian S, Arnold N,
Engel C, Deissler H, Rhiem K, Niederacher D, Plendl H, Sutter C,
Wappenschmidt B, Borg A, Melin B, Rantala J, Soller M, Nathanson KL,
Domchek SM, Rodriguez GC, Salani R, Kaulich DG, Tea MK, Paluch SS, Laitman
Y, Skytte AB, Kruse TA, Jensen UB, Robson M, Gerdes AM, Ejlertsen B,
Foretova L, Savage SA, Lester J, Soucy P, Kuchenbaecker KB, Olswold C,
Cunningham JM, Slager S, Pankratz VS, Dicks E, Lakhani SR, Couch FJ, Hall
P, Monteiro AN, Gayther SA, Pharoah PD, Reddel RR, Goode EL, Greene MH,
Easton DF, Berchuck A, Antoniou AC, Chenevix-Trench G, Dunning AM.
Multiple independent variants at the TERT locus are associated with
telomere length and risks of breast and ovarian cancer. Nat Genet
45(4):371-84, 2013. PMID: 23535731.
114. Torres KE, Ravi V, Kin K, Yi M, Guadagnolo BA, May CD, Arun BK, Hunt KK,
Lam R, Lahat G, Hoffman A, Cormier JN, Feig BW, Lazar AJ, Lev D, Pollock
RE. Long-term outcomes in patients with radiation-associated angiosarcomas
of the breast following surgery and radiotherapy for breast cancer. Ann
Surg Oncol 20(4):1267-74, 2013. e-Pub 2012. PMID: 23224828.
115. Bayraktar S, Gutierrez-Barrera AM, Liu D, Pusztai L, Litton J, Valero V,
Hunt K, Hortobagyi GN, Wu Y Symmans WF, Arun B. USP-11 as a predictive and
prognostic factor following neoadjuvant therapy in women with breast
cancer. Cancer J 19(1):10-17, 2013. PMID: 23337751.
116. Bayraktar S, Thompson PA, Yoo SY, Do KA, Sahin AA, Arun BK, Bondy ML,
Brewster AM. The relationship between eight GWAS-identified
single-nucleotide polymorphisms and primary breast cancer outcomes.
Oncologist 18(5):493-500, 2013. e-Pub 2013. PMID: 23635555.
117. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P,
Fredericsen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey
S, Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S,
Stoppa-Lyonnet D, Jakubowska A, Investigators K, Radice P, Schmutzler RK,
SWE-BRCA, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M,
Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Szabo CI, Blanco
I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah
E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna
H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Ewart
Toland A, Caligo MA, Olopade Ol, Tung N, Claes K, Beattie MS, Southey MC,
Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O,
Balmana J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell
I, van der Hout AH, van Deurzen CH, Seynaeve C, Gómez Garcia EB, van
Leeuwen FE, Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg
MJ, Rookus MA, Devilee P, Verhoef S, van Os TA, Wijnen JT; HEBON; EMBRACE,
Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA,
Adlard J, Eccles DM, Cook J, Brewer C, Douglas F, Hodgson S, Morrison PJ,
Side LE, Donaldson A, Houghton C, Rogers MT, Dorkins H, Eason J, Gregory
H, McCann E, Murray A, Calender A, Hardouin A, Berthet P, Delnatte C,
Nogues C, Lasset C, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola F,
Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Léoné
M, Pujol P, Mazoyer S, Bignon YJ; GEMO Study Collaborators,
Złowocka-Perłowska E, Gronwald J, Lubinski J, Durda K, Jaworska K,
Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, Melloni G, Ottini L,
Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian S,
Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K,
Rhiem K, Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S,
Engert S, Sutter C,. . .CIMB. Genome-wide association study in BRCA1
mutation carriers identifies novel loci associated with breast and ovarian
cancer risk. PloS Genet 9(3):e1003212. doi: 10.1371, 2013. e-Pub 2013.
PMID: 23544013.
118. Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready
K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun BK. Genotype in
BRCA-associated breast cancers. Breast J 19(1):87-91, 2013. e-Pub 2012.
PMID: 23231005.
119. de la Cruz J, Andre F, Harrell RK, Bassett RL Jr, Arun B, Mathieu MC,
Delaloge S, Gilcrease MZ. Tissue-based predictors of germ-line BRCA1
mutations: implications for triaging of genetic testing. Hum Pathol
43(11):1932-1939, 2012. e-Pub 2012. PMID: 22591913.
120. Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK,
Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang RF,
Bedrosian I, Hunt KK, Kuerer HM. Biology, treatment, and outcome in very
young and older women with DCIS. Ann Surg Oncol 19(12):3777-784, 2012.
e-Pub 2012. PMID: 22622473.
121. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL,
Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A,
Terry MB, Santella RM, Lippman SM, Hershman DL. Phase IB randomized,
double-blinded, placebo-controlled, dose escalation study of polyphenon E
in women with hormone receptor-negative breast cancer. Cancer Prev Res
(Phila) 5(9):1144-1154, 2012. e-Pub 2012. PMID: 22827973.
122. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y,
Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT. Invasive paget
disease of the breast: Clinicopathologic study of an underrecognized
entity in the breast. Am J Surg Pathol 36(9):1353-8, 2012. PMID: 22895267.
123. Kumar NB, Vadaparampil ST, Mahajan N, Lilienfeld HS, Lee JH, Laronga C,
Hakam A, Hein JJ, Egan KM, Arun B, Pal T. Metformin- A Promising Agent for
Chemoprevention in BRCA1 Carriers. Hereditary Genet 1(2):pii: 104, 2012.
PMID: 26097796.
124. Kuerer HM, Lari SA, Arun B, Hu CY, Brewster A, Mittendorf EA, Albarracin
CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I,
Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of
ductal carcinoma in situ are not adversely impacted by initial large body
mass. Breast Cancer Res Treat 133(3):1131-41, 2012. e-Pub 2012. PMID:
22392043.
125. Bayraktar S, Arun B. Dose-dense chemotherapy for breast cancer. Breast J
18(3):261-6, 2012. PMID: 22583196.
126. Litton JK, Bevers TB, Arun BK. Exemestane in the prevention setting. Ther
Adv Med Oncol 4(3):107-12, 2012. PMID: 22590484.
127. Wang LE, Han CH, Xiong P, Bondy ML, Yu TK, Brewster AM, Shete S, Arun B,
Buchholz TA, Wei Q. Gamma-ray-induced mutagen sensitivity and risk of
sporadic breast cancer in young women: a case-control study. Breast Cancer
Res Treat 132(3):1147-55, 2012. e-Pub 2012. PMID: 22218884.
128. Bayraktar S, Elsayegh N, Gutierrez-Barerra AM, Lin H, Kuerer H, Tasbas T,
Muse KI, Ready K, Litton J, Meric-Bernstram F, Hortobagyi GN, Albarracin
CT, Arun B. Predictive factors for BRCA1/BRCA2 mutations in women with
ductal carcinoma in situ. Cancer 118(6):1515-22, 2012. e-Pub 2011. PMID:
22009639.
129. Litton JK, Arun BK, Brown PH, Hortobagyi GN. Aromatase inhibitors and
breast cancer prevention. Expert Opin Pharmacother 13(3):325-31, 2012.
e-Pub 2012. PMID: 22242911.
130. Arun BK, Valero V, Liu D, Brewster AM, Green M, Gutierrez-Barerra A, Green
M, Gutierrez-Barerra AM, Akar U, Rivera E, Esteva FJ, Buzdar AU,
Hortobagyi GN, Sneige N. Short-term biomarker modulation prevention study
of anastrozole in women at increased risk for second primary breast
cancer. Cancer Prev Res 5(2):276-82, 2012. e-Pub 2011. PMID: 22102688.
131. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD,
Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC,
Arun BK. Early onset HER2-positive breast cancer is associated with
germline TP53 mutations. Cancer 118(4):908-13, 2012. e-Pub 2011. PMID:
21761402.
132. Biswas S, Tankhiwale N, Blackford A, Barrera AM, Ready K, Lu K, Amos CI,
Parmigiani G, Arun B. Assessing the added value of breast tumor markers in
genetic risk prediction model BRCAPRO. Breast Cancer Res Treat
133(1):347-55, 2012. e-Pub 2012. PMID: 22270937.
133. Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam
F, Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BK. Earlier
age of onset of BRCA mutation-related cancers in subsequent generations.
Cancer 118(2):321-5, 2012. e-Pub 2011. PMID: 21913181.
134. Ready K, Arun B, Schmeler KM, Uyei A, Litton JK, Lu KH, Sun CC, Peterson
SK. Communication of BRCA1 and BRCA2 genetic test results to health care
providers following genetic testing at a tertiary care center. Fam Cancer
10(4):673-9, 2011. PMID: 21681553.
135. Ready K, Arun B, Schmeler KM, Litton JK, Lu KH, Sun CC, Peterson SK.
Communication of BRCA1 and BRCA2 genetic test results to health care
providers following genetic testing at a tertiary care center. Fam Cancer
10(4):673-9, 2011. PMID: 21681553.
136. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin
E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN,
Arun BK. Outcome of triple-negative breast cancer in patients with or
without deleterious BRCA mutations. Breast Cancer Res Treat 130(1):145-53,
2011. e-Pub 2011. PMID: 21830012.
137. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L,
Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C.
Response to neoadjuvant systemic therapy for breast cancer in BRCA
mutation carriers and noncarriers: a single-institution experience. J Clin
Oncol 28(29):3739-3746, 2011. e-Pub 2011. PMID: 21900106.
138. Roses RE, Arun B, Lari SA, Mittendorf EA, Lucci A, Hunt KK, Kuerer HM.
Ductal carcinoma-in-situ of the breast with subsequent distant metastasis
and death. Ann Surg Oncol 18(10):2873-8, 2011. e-Pub 2011. PMID: 21476105.
139. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A,
Hortobagyi GN, Litton JK, Arun BK. Effectiveness of alternating
mammography and magnetic resonance imaging for screening women with
deleterious BRCA mutations at high risk of breast cancer. Cancer
117(17):3900-3907, 2011. e-Pub 2011. PMID: 21365619.
140. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, Johnson KG,
Daniels MS, Arun B, Peterson SK, Bodurka DC. Satisfaction with ovarian
carcinoma risk-reduction strategies among women at high risk for breast
and ovarian carcinoma. Cancer 117(12):2659-2667, 2011. e-Pub 2010. PMID:
21656744.
141. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF,
Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H. Preventive
therapy for breast cancer: a consensus statement. Lancet Oncol
12(5):496-503, 2011. PMID: 21441069.
142. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J,
Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun B, Hortobagyi GN, Do KA,
Mills GB, Meric-Bernstam F.. Incidence and outcome of BRCA mutations in
unselected patients with triple receptor-negative breast cancer. Clin
Cancer Res 17(5):1082-1089, 2011. e-Pub 2011. PMID: 21233401.
143. Ready K, Gutierrez-Barrera A, Atchley D, Solomon K, Amos C, Meric-Bernstam
F, Lu K, Hortobagyi G, Arun BK. Cancer risk management decisions of women
with BRCA1 or BRCA2 variants of uncertain significance. Breast J
17(2):210-2, 2011. e-Pub 2011. PMID: 21294809.
144. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin
G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E,
Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized
trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in
locally advanced breast cancer: long-term results. Oncologist
16(11):1527-34, 2011. e-Pub 2011. PMID: 22042783.
145. Cohen L, Chen Z, Arun B, Shao Z, Dryden M, Xu L, LePetross C, Dogan B,
McKenna BJ, Markman M, Babiera G. External qigong therapy for women with
breast cancer prior to surgery. Integrative Cancer Therapies 9(4):348-353,
2010. PMID: 21106615.
146. Zhang D, Tari AM, Akar U, Arun B, LaFortune TA, Nieves-Alicea R,
Hortobagyi GN, Ueno NT. Silencing kinase-interacting stathmin gene
enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in
epidermal growth factor receptor-expressing breast cancer. Mol Cancer Ther
9(11):3090-9, 2010. e-Pub 2010. PMID: 21045138.
147. Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F, Kathleen Cuningham
Consortium for Research into Familial Breast Cancer, Lee E, Ursin G,
Rebbeck TR, Domchek SM, Arun B, Susswein L, Isaacs C, Garber JE,
Visvanathan K, Griffin CA, Sutphen R, Brzosowicz J, Gruber S, Finkelstein
DM, Schildkraut JM. Evaluation of established breast cancer risk factors
as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast
Cancer Res Treat 124(2):441-51, 2010. e-Pub 2010. PMID: 20309627.
148. Ready K, Arun B. Clinical assessment of breast cancer risk based on family
history. J Natl Compr Canc Netw 8(10):1148-55, 2010. PMID: 20971839.
149. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I,
Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C,
Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L,
Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH. Breast cancer
risk reduction. J Natl Compr Cancer Netw 8(10):1112-46, 2010. PMID:
20971838.
150. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B.
Expanding the criteria for BRCA mutation testing in breast cancer
survivors. J Clin Oncol 28(27):4214-20, 2010. e-Pub 2010. PMID: 20733129.
151. Brandt AC, Tschirgi ML, Ready KJ, Sun C, Darilek S, Hecht J, Arun B, Lu
KH. Knowledge, attitudes, and clinical experience of physicians regarding
preimplantation genetic diagnosis for hereditary cancer predisposition
syndromes. Fam Cancer 9(3):479-487, 2010. PMID: 20431955.
152. Carlson RW, Theriault R, Schurman CM, Rivera E, Chung CT, Phan SC, Arun B,
Dice K, Chiv VY, Green M, Valero V. Phase II trial of anastrozole plus
goserelin in the treatment of hormone receptor-positive, metastatic
carcinoma of the breast in premenopausal women. J Clin Oncol
28(25):3917-3921, 2010. e-Pub 2010. PMID: 20679610.
153. Yi M, Hunt KK, Arun B, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera
GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F. Factors affecting
the decision of breast cancer patients to undergo contralateral
prophylactic mastectomy. Cancer Prev Res 3(8):1026-1034, 2010. e-Pub 2010.
PMID: 20647335.
154. Arun B, Dunn BK, Ford LG, Ryan A. Breast cancer prevention trials: large
and small trials. Semin Oncol 37(4):367-383, 2010. PMID: 20816507.
155. Han CH, Lu J, Wei Q, Bondy ML, Brewster AM, Yu TK, Buchholz TA, Arun B,
Wang LE. The funtional promoter polymorphism (-842G>C) in the PIN1 gene is
associated with decreased risk of breast cancer in non-Hispanic white
women 55 years and younger. Breast Cancer Res Treat 122(1):243-249, 2010.
e-Pub 2009. PMID: 20033770.
156. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander
M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens
M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in
patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a
proof-of-concept trial. Lancet 376(9737):235-244, 2010. e-Pub 2010. PMID:
20609467.
157. Arun BK, Granville LA, Yin G, Middleton LP, Dawood S, Kau SW, Kamal A, Hsu
L, Hortobagyi GN, Sahin AA. Glutathione-s-transferase-pi expression in
early breast cancer: association with outcome and response to
chemotherapy. Cancer Invest 28(5):554-559, 2010. PMID: 20210524.
158. Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT,
Hortobagyi GN, Arun B. Targeting p70S6K prevented lung metastasis in a
breast cancer xenograft model. Mol Cancer Ther 9(5):1180-7, 2010. e-Pub
2010. PMID: 20423989.
159. Ready K, Litton JK, Arun BK. Clinical application of breast cancer risk
assessment models. Future Oncol 3(6):355-365, 2010. PMID: 20222793.
160. Perez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, Kimmick GG, Cohen
I, Shtivelman E, Caygill KA, Grady D, Schactman M, Shapiro CL. A phase 1B
dose escalation trial of Scutellaria barbata (BZL101) for patients with
metastatic breast cancer. Breast Cancer Res Treat 120(1):111-8, 2010.
PMID: 20054647.
161. Perez A, Arun B, Tripathy D, Tagliaferri M, Shaw H, Kimmick G, Cohen I,
Shtivelman E, Caygill KA, Grady D, Schactman M, Wittes J, Shapiro C. Phase
1B dose escalation trial of scutellaria barbata (BZL 101) for patients
with metastatic breast cancer. Breast Cancer Res Treat 120(1):111-118,
2010. PMID: 20054647.
162. Chandwani KD, Thornton B, Perkins GH, Arun B, Raghuram NV, Nagendra HR,
Wei Q, Cohen L. Yoga improves quality of life and benefit finding in women
undergoing radiotherapy for breast cancer. J Soc Integr Oncol 8(2):43-55,
2010. PMID: 20388445.
163. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C,
Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC.
Decreased TGFbeta signaling and increased COX2 expression in high risk
women with increased mammographic breast density. Breast Cancer Res Treat
119(2):305-314, 2010. e-Pub 2009. PMID: 19241157.
164. Rixe O, Franco S, Yardley D, Johnston S, Martin M, Arun B, Letrent S. A
randomized, phase II, dose-finding study of the pan-ErbB receptor
tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic
breast cancer. Cancer Chemother Pharmacol 64(6):1139-48, 2009. e-Pub 2009.
PMID: 19294387.
165. Huflejt ME, Vuskovic M, Vasiliu D, Xu H, Obukhova P, Shilova N, Tuzikov A,
Galanina O, Arun B, Lu K, Bovin N. Anti-carbohydrate antibodies of normal
sera: findings, surprises and challenges. Mol Immunol 46(15):3037-49,
2009. e-Pub 2009. PMID: 19608278.
166. Visvanathan K, Chlebowski, TR, Hurley P, Col NF, Ropka M, Collyar D,
Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG,
Wade JL Brown P, Cuzick J, Kramer BS, Lippman SM. American society of
clinical oncology clinical practice guideline update on the use of
pharmacologic interventions including tamoxifen, raloxifene, and aromatase
inhibition for breast cancer risk reduction. J Clin Oncol
27(19):3235-3258, 2009. e-Pub 2009. PMID: 19470930.
167. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F,
Gonzalez-Angulo AM, Bodurka DC, Lu KH, HortobagyiGN, Arun B. Perception of
screening and risk reduction surgeries in patients tested for a BRCA
deleterious mutation. Cancer 115(8):1598-604, 2009. PMID: 19280625.
168. Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera GV,
Hwang RF, Kuerer HM, Yang W, Hunt KK. Predictors of contralateral breast
cancer in patients with unilateral breast cancer undergoing contralateral
prophylactic mastectomy. Cancer 115(5):962-971, 2009. PMID: 19172584.
169. Ready KJ, Vogel KJ, Atchley DP, Broglio KR, Solomon KK, Amos C, Lu KH,
Hortobagyi GN, Arun B. Accuracy of the BRCAPRO model among women with
bilateral breast cancer. Cancer 115(4):725-730, 2009. PMID: 19127556.
170. Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI,
Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CT. High prevalence
of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.
Cancer Prev Res 2(2):122-7, 2009. e-Pub 2009. PMID: 19174581.
171. Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, Robson ME,
Domchek SM, Hartmann LC, Holland R, Winchester DJ, Winchester DJ, Anderson
BO, Arun B, Bartelink H, Bernard P, Bonanni B, Cady B, Clough KB, Feig SA,
Heywang-Köbrunner SH, Howell A, Isaacs C, Kopans DB, Mansel RE, Masood S,
Palazzo JP, Pressman PI, Solin LJ, Untch M. Proceedings of the
international consensus conference on breast cancer risk, genetics, & risk
management, April, 2007. Breast J 15(1):4-16, 2009. PMID: 19141130.
172. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF,
Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton
ME, Czerniecki BJ, Arun B, Hortobagyi GN. Ductal carcinoma in situ: state
of the science and roadmap to advance the field. J Clin Oncol
27(2):279-88, 2009. e-Pub 2008. PMID: 19064970.
173. Eralp Y, Smith TL, Altundag K, Kau SW, Litton J, Valero V, Buzdar A,
Hortobagyi GN, Arun B. Clinical features associated with a favorable
outcome following neoadjuvant chemotherapy in women with localized breast
cancer aged 35 years or younger. J Cancer Res Clin Oncol 135(1):141-8,
2009. e-Pub 2008. PMID: 18581139.
174. Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin
A, Albarracin CT. Loss of annexin A1 expression in breast cancer
progression. Appl Immunohistochem Mol Morphol 16(6):530-4, 2008. PMID:
18776816.
175. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D,
Booser DJ, Green MC, Arun B, Pusztai L, Lopez A, Islam R, Valero V,
Hortobagyi GN. Imatinib mesylate (Gleevec) in advanced breast
cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological
correlations. Ann Oncol 19(10):1713-9, 2008. e-Pub 2008. PMID: 18515258.
176. Atchley D, Albarracin C, Lopez A, Valero V, Amos V, Gonzalez-Angulo A,
Hortobagyi G, Arun B. Clinical and pathologic characteristics of patients
with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol
26(26):4282-8, 2008. PMID: 18779615.
177. Brewster A, Hortobagyi G, Broglio K, Kau S, Santa-Maria C, Arun B, Amad U,
Buzdar A, Booser D, Valero V, Esteva F. Residual risk of breast cancer
recurrence 5 years after adjuvant therapy. J Natl Cancer Inst
100(16):1179-83, 2008. e-Pub 2008. PMID: 18695137.
178. Mazouni C, Arun B, André F, Ayers M, Krishnamurthy Wang B, Hortobagyi GN,
Buzdar AU, Pusztai L.. Collagen IV levels are elevated in the serum of
patients with primary breast cancer compared to healthy volunteers. Br J
Cancer 99(1):68-71, 2008. e-Pub 2008. PMID: 18560403.
179. Akar U, Chaves-Reyes A, Barria M, Tari A, Saungino A, Kondo Y, Kondo S,
Arun B, Lopez-Berestein G, Ozpolat B.. Silencing of Bcl-2 expression by
small interfering RNA induces autophagic cell death in MCF-7 breast cancer
cells. Autophagy 4(5):669-79, 2008. e-Pub 2008. PMID: 18424910.
180. Wang H, Arun B, Wang H, Fuller GN, Zhang W, Middleton LP, Sahin AA. IGFBP2
and IGFBP5 overexpression correlates with the lymph node metastasis in T1
breast carcinomas. Breast J 14(3):261-7, 2008. e-Pub 2008. PMID: 18373644.
181. Batista L, Lu KH, Beahm EK, Arun B, Bodukra D, Meric-Bernstam F.
Coordinated prophylactic surgical management for women with hereditary
breast-ovarian cancer syndrome. BMC Cancer 8:101, 2008. PMID: 18410690.
182. Rivera E, Mejia J, Arun B, Adinin R, Walters R, Brewster A, Broglio K, Yin
G, Hortobagyi G, Valero V. Phase 3 study comparing the use of docetaxel on
an every-3-week versus weekly schedule in the treatment of metastatic
breast cancer. Cancer 112(7):1455-61, 2008. PMID: 18300256.
183. Er O, Frye DK, Kau SW, Broglio K, Valero V, Hortobagyi GN, Arun B.
Clinical course of breast cancer patients with metastases limited to the
liver treated with chemotherapy. Cancer J 14(1):62-8, 2008. PMID:
18303485.
184. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortonagyi GN,
Arun B. Multifocal breast cancer in women < or =35 years old. Cancer
110(7):1445-50, 2007. PMID: 17676585.
185. Vogel K, Atchley DP, Erlichman J, Broglio K, Ready KR, Valero V, Amos CI,
Hortobagyi GN, Lu KH, Arun B. BRCA1 and BRCA2 genetic testing in Hispanic
patients: mutation prevalence and evaluation of the BRCAPRO risk
assessment model. J Clin Oncol 25(29):4635-41, 2007. PMID: 17925560.
186. Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, Yin G, Green
M, Kuerer H, Gong Y, Browne D, Hortobagyi G, Sneige N. Comparison of
ductal lavage and random periareolar fine needle aspiration as tissue
acquisition methods in early breast cancer prevention trials. Clin Cancer
Res 13(16):4943-48, 2007. PMID: 17699874.
187. Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K,
Meric-Bernstam F, Amos C, Strong L, Arun B. Association between clinical
characteristics and risk-reduction interventions in women who underwent
BRCA1 and BRCA2 testing: a single-institution study. Cancer
107(12):2745-51, 2006. PMID: 17109443.
188. Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Kuerer HM, Singletary
SE, Babiera GV, Arun B, Hunt KK, Bedrosian I. Selective use of sentinel
lymph node surgery during prophylactic mastectomy. Cancer 107(7):1440-7,
2006. PMID: 16955504.
189. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman
JL, Arun B, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR,
Gershenson DM, Lu KH. Prophylactic bilateral salpingo-oophorectomy
compared with surveillance in women with BRCA mutations. Obstet Gynecol
108(3 Pt 1):515-20, 2006. PMID: 16946209.
190. Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, Broglio K, Yin
G, Hortobagyi GN, Buchholz T. Phase I study of capecitabine in combination
with temozolomide in the treatment of patients with brain metastases from
breast carcinoma. Cancer 107(6):1348-54, 2006. PMID: 16909414.
191. Cristofanilli M, Krishnamurthy S, Guerra L, Broglio K, Arun B, Booser DJ,
Menander K, Van Wart Hood J, Valero V, Hortobagyi GN. A nonreplicating
adenoviral vector that contains the wild-type p53 transgene combined with
chemotherapy for primary breast cancer: safety, efficacy, and biologic
activity of a novel gene-therapy approach. Cancer 107(5):935-44, 2006.
PMID: 16874816.
192. Garland LL, Hidalgo M, Mendelson DS, Ryan DP, Arun B, Lovalvo JL, Eiseman
IA, Olson SC, Lenehan PF, Eder JP. A phase I clinical and pharmacokinetic
study of oral CI-1033 in combination with docetaxel in patients with
advanced solid tumors. Clin Cancer Res 12(14 Pt 1):4274-82, 2006. PMID:
16857802.
193. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ,
Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R,
Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE,
Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ,
Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM,
Engstrom PF, Meyskens FL, Jr, O'Shaughnessy J, Hawk ET, Levin B, Nelson
WG, Hong WK. Progress in chemoprevention drug development: the promise of
molecular biomarkers for prevention of intraepithelial neoplasia and
cancer--a plan to move forward. Clin Cancer Res 12(12):3661-97, 2006.
PMID: 16778094.
194. Sneige N, Liu B, Yin G, Gong Y, Arun B. Correlation of cytologic findings
and chromosomal instability detected by fluorescence in situ hybridization
in breast fine-needle aspiration specimens from women at high risk for
breast cancer. Mod Pathol 19(5):622-29, 2006. PMID: 16528376.
195. Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N,
Pusztai L, Buchholz TA, Sahin A, Hunt KK, Meric-Bernstam F, Ross MI, Ames
FC, Kuerer HM.. Impact of concurrent proliferative high-risk lesions on
the risk of ipsilateral breast carcinoma recurrence and contralateral
breast carcinoma development in patients with ductal carcinoma in situ
treated with breast-conserving therapy. Cancer 106(1):42-50, 2006. PMID:
16333852.
196. Barcenas CH, Hosain GM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills
GB, Tomlinson GE, Miller AR, Strong LC, Amos CI.. Assessing BRCA carrier
probabilities in extended families. J Clin Oncol 24(3):354-60, 2006. PMID:
16421416.
197. Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec
J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault
RL, Arun B, Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai L. A
single-gene biomarker identifies breast cancers associated with immature
cell type and short duration of prior breastfeeding. Endocr Relat Cancer
12(4):1059-69, 2005. PMID: 16322343.
198. Mangala LS, Arun B, Sahin AA, Mehta K.. Tissue transglutaminase-induced
alterations in extracellular matrix inhibit tumor invasion. Mol Cancer
4:33, 2005. PMID: 16153302.
199. Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin
A.. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node
metastasis in T1 breast cancer. Clin Cancer Res 11(16):5686-93, 2005.
200. Suriano G, Yew S, Ferreira P, Senz J, Kaurah P, Ford JM, Longacre TA,
Norton JA, Chun N, Young S, Oliveira MJ, Macgillivray B, Rao A, Sears D,
Jackson CE, Boyd J, Yee C, Deters C, Pai GS, Hammond LS, McGivern BJ,
Medgyesy D, Sartz D, Arun B, Oelschlager BK, Upton MP, Neufeld-Kaiser W,
Silva OE, Donenberg TR, Kooby DA, Sharma S, Jonsson BA, Gronberg H,
Gallinger S, Seruca R, Lynch H, Huntsman DG. Characterization of a
recurrent germ line mutation of the E-cadherin gene: implications for
genetic testing and clinical management. Clin Cancer Res 11(15):5401-9,
2005. PMID: 16061854.
201. Arun B, Kilic G, Yen C, Foster B, Yardley DA, Gaynor R, Ashfaq R. Loss of
FHIT expression in breast cancer is correlated with poor prognostic
markers. Cancer Epidemiol Biomarkers Prev 14(7):1681-5, 2005. PMID:
16030101.
202. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL,
Pusztai L, Green MC, Arun B, Giordano SH, Cristofanilli M, Frye DK, Smith
TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D,
Hortobagyi GN. Significantly higher pathologic complete remission rate
after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin
chemotherapy: results of a randomized trial in human epidermal growth
factor receptor 2-positive operable breast cancer. J Clin Oncol
23(16):3676-85, 2005. e-Pub 2005. PMID: 15738535.
203. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS,
Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans
WF, Pusztai L. Microtubule-associated protein tau: a marker of paclitaxel
sensitivity in breast cancer. Proc Natl Acad Sci USA 102(23):8315-20,
2005. PMID: 15914550.
204. Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V,
Theriault R, Booser D, Buzdar AU, Hortobagyi GN, Arun B. Women age < or =
35 years with primary breast carcinoma: disease features at presentation.
Cancer 103(12):2466-72, 2005. PMID: 15852360.
205. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK,
Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM. Significant
differences in nipple aspirate fluid protein expression between healthy
women and those with breast cancer demonstrated by time-of-flight mass
spectrometry. Breast Cancer Res Treat 89(2):149-57, 2005. PMID: 15692757.
206. Kilic G, Gurates B, Garon J, Kang H, Arun B, Lampley CE, Kurzel R, Ashfaq
R. Expression of cyclooxygenase-2 in endometrial adenocarcinoma. Eur J
Gynaecol Oncol 26(3):271-4, 2005. PMID: 15991524.
207. Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM,
Babiera GV, Ames FC, Ross MI, Feig BW, Sahin AA, Arun B, Meric-Bernstam F.
Contralateral prophylactic mastectomy. Predictors of significant
histologic findings. Cancer 101(9):1977-86, 2004. PMID: 15389473.
208. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M,
Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G,
Ross J, Sneige N, Hortobagyi GN, Pusztai L. Gene expression profiles
predict complete pathologic response to neoadjuvant paclitaxel and
fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast
cancer. J Clin Oncol 22(12):2284-93, 2004. e-Pub 2004. PMID: 15136595.
209. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A,
Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E,
Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of
inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine
25(3):94-102, 2004. PMID: 14698135.
210. Ozguroglu M, Avci B, Turna H, Esen G, Arun B, Celik V, Serdengecti S.
Should mammographic screening be done in primary ovarian cancer? A case
control study in Turkish women. Med Oncol 21(2):139-43, 2004. PMID:
15299186.
211. Altundag K, Altundag O, Gunduz M, Arun B. Possible interaction between
activator protein-1 and proto-oncogene B-cell lymphoma gene 6 in breast
cancer patients resistant to tamoxifen. Med Hypotheses 63(5):823-6, 2004.
PMID: 15488654.
212. Arun B, Kilic G, Yen C, Foster B, Yardley D, Gaynor R, Ashfaq R.
Correlation of Bcl-2 and p53 expression in primary breast tumors and
corresponding metastatic lymph nodes. Cancer 98(12):2554-9, 2003. PMID:
14669273.
213. Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade
JL, 3rd, Pusztai L, Hortobagyi GN. Phase II study of pegylated liposomal
doxorubicin in combination with gemcitabine in patients with metastatic
breast cancer. J Clin Oncol 21(17):3249-54, 2003. PMID: 12947059.
214. Pusztai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, Nealy KM,
Gibbs A, Symmans WF, Esteva FJ, Booser D, Murray JL, Valero V, Smith TL,
Hortobagyi GN. Phase I and II study of exisulind in combination with
capecitabine in patients with metastatic breast cancer. J Clin Oncol
21(18):3454-61, 2003. PMID: 12972520.
215. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige
N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M,
Valero V, Adams C, Hortobagyi GN, Symmans WF. Gene expression profiles
obtained from fine-needle aspirations of breast cancer reliably identify
routine prognostic markers and reveal large-scale molecular differences
between estrogen-negative and estrogen-positive tumors. Clin Cancer Res
9(7):2406-15, 2003. PMID: 12855612.
216. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L,
Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL,
Hortobagyi GN. Phase II study of weekly docetaxel and trastuzumab for
patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol
20(7):1800-8, 2002. PMID: 11919237.
217. Arun B, Kilic G, Ashfaq R, Saboorian HM, Gokaslan T. Endothelin converting
enzyme-1 expression in endometrial adenocarcinomas. Cancer Invest
19(8):779-82, 2001. PMID: 11768030.
218. Yang WT, Dryden M, Broglio, K, Gilcrease M, Dawood S, Dempsey PJ, Valero
V, Hortobagyi G, Atchley D, Arun B. Mammographic features of triple
receptor-negative primary breast cancers in young premenopausal women.
Breast Cancer Res Treat 111(3):405-10, 2000. e-Pub 2007. PMID: 18026834.
219. Ozguroglu M, Arun B, Demir G, Demirelli F, Mandel NM, Buyukunal E,
Serdengecti S, Berkarda B. Serum erythropoietin level in anemic cancer
patients. Med Oncol 17(1):29-34, 2000. PMID: 10713657.
220. Arun B, Curti BD, Longo DL, Stevens D, Alvord WG, Gause BL, Watson T, Kopp
WC, Janik JE. Elevations in serum soluble interleukin-2 receptor levels
predict relapse in patients with hairy cell leukemia. Cancer J Sci Am
6(1):21-4, 2000. PMID: 10696734.
221. Ozguroglu M, Arun B, Erzin Y, Demir G, Demirelli F, Mandel NM, Buyukunal
E, Serdengecti S, Berkarda B. Serum cardiolipin antibodies in cancer
patients with thromboembolic events. Clin Appl Thromb Hemost 5(3):181-184,
1999. PMID: 10726005.
222. Meehan KR, Arun B, Gehan EA, Berberian B, Sulica V, Areman EM, Mazumder A,
Lippman ME. Immunotherapy with interleukin-2 and alpha-interferon after
IL-2-activated hematopoietic stem cell transplantation for breast cancer.
Bone Marrow Transplant 23(7):667-73, 1999. PMID: 10218842.
223. Arun B, Slack R, Gehan E, Spitzer T, Meehan KR. Survival after autologous
hematopoietic stem cell transplantation for patients with inflammatory
breast carcinoma. Cancer 85(1):93-9, 1999. PMID: 9921979.
224. Arun B, Berberian B, Azumi N, Frankel SR, Luksenburg H, Freter C. Sweet's
syndrome during treatment with all-trans retinoic acid in a patient with
acute promyelocytic leukemia. Leuk Lymphoma 31(5-6):613-5, 1998. PMID:
9922053.
225. Oates AJ, Schumaker LM, Jenkins SB, Pearce AA, DaCosta SA, Arun B, Ellis
MJ. The mannose 6-phosphate/insulin-like growth factor 2 receptor
(M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res
Treat 47(3):269-81, 1998. PMID: 9516081.
INVITED ARTICLES
1. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I,
Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C,
Lawton T, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Seewaldt V,
Sellin RV, Shapiro CL, Singletary E, Ward JH.. Breast cancer risk
reduction. J Natl Compr Cancer Netw 5(8):676-01, 2007. PMID: 17927926.
2. Arun B, Brown PH, Garber JE. Risk assessment and efficacy of pharmacologic
agents in breast cancer. Updates in Current Clinical Practices 1:5-8, 2006.
3. Arun B. Ductal lavage and risk assessment of breast cancer. Oncologist
9(6):599-05, 2004. PMID: 15561804.
4. Arun B. An overview of breast cancer prevention trials. The American
Journal of Oncology Review:492-94, 2003.
5. Arun B. Management of women at high risk for breast cancer. JNCCN
1(1):S71-77, 2003.
6. Esteva FJ, Sahin AA, Cristofanilli M, Arun B, Hortobagyi GN. Molecular
prognostic factors for breast cancer metastasis and survival. Semin Radiat
Oncol 12(4):319-28, 2002. PMID: 12382190.
7. Arun B, Anthony M, Dunn B. The search for the ideal SERM. Expert Opin
Pharmacother 3(6):681-91, 2002. PMID: 12036407.
8. Arun B, Hortobagyi GN. Progress in breast cancer chemoprevention. Endocr
Relat Cancer 9(1):15-32, 2002. PMID: 11914180.
9. Arun B. Preventive strategies for breast cancer. Breast Cancer: Management
and Treatment Updates 1:1-11, 2002.
10. Arun B, Frenkel EP. Topoisomerase I inhibition with topotecan:
pharmacologic and clinical issues. Expert Opin Pharmacother 2(3):491-505,
2001. PMID: 11336601.
11. Bick RL, Arun B, Frenkel EP. Antiphospholipid-thrombosis syndromes.
Haemostasis 29(2-3):100-10, 1999. PMID: 10629391.
12. Bick RL, Arun B, Frenkel EP. Disseminated intravascular coagulation.
clinical and pathophysiological mechanisms and manifestations. Haemostasis
29(2-3):111-34, 1999. PMID: 10629392.
13. Kilic G, Cardillo M, Ozdemirli M, Arun B. Human papillomavirus 18
oncoproteins E6 and E7 enhance irradiation- and chemotherapeutic
agent-induced apoptosis in p53 and Rb mutated cervical cancer cell lines.
Eur J Gynaecol Oncol 20(3):167-71, 1999. PMID: 10410876.
14. Longo DL, Arun B. Clinical approach to cervical lymphadenopathy. Consultant
36(11):2345-2352, 1996.
MANUALS, TEACHING AIDS, OTHER TEACHING PUBLICATIONS
1. Arun B. Genetic testing for hereditary breast cancer, 2015.
2. Arun B. Management of high-risk patients. Breast Cancer and Genetics
Oncology, 2013.
3. Arun B. Risk assessment and genetic testing. Breast Cancer and Genetics
Oncology, 2013.
4. Arun B. Possible link discovered in Hispanic women and breast cancer. CBS -
KHOU TV: Houston, Texas, 2007.
5. Arun B. The role BRCA mutations play in breast cancer risk. Golf for Women
Magazine, 2007.
OTHER ARTICLES
1. Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey A, Strong L, Shaw K,
Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK, Aytac U,
Routbort M, Subbiah V, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB,
Chen K Incidental germline variants in 1000 advanced cancers on a
prospective somatic genomic profiling protocol. Ann Oncol 27(5):795-800,
2016. PMID: 26787237.
2. Ready K, Litton JK, Arun B Clinical application of breast cancer risk
assessment models. Future Oncology 6(3):355-365, 2010. PMID: 20222793.
3. Arun B Commentary on the article Fenretinide Breast Cancer Prevention Trial:
Drug and retinol plasma levels in relation to age and disease outcome.
Breast Disease: A Year Book Quarterly, 2003.
ABSTRACTS
1. Kizub DA, Bluebond R, Green S, Duckworth J, Shanker S, Vara A, Joseph B,
Arun B. Improving access to cancer genetic testing for underserved women in
southeast Texas. 2022 ASCO Annual Meeting. Citation: J Clin Oncol 40(Suppl
16; abstr 6548), 2022.
2. Dodd-Eaton EB, Nguyen HN, Corredor J, Woodman-Ross J, Peng G, Green S,
Hernandez ND, Gutierrez Barrera A, Arun B, Wang W. Determining concordance
of LFSPRO TP53 germline carrier risk predictions to standard genetic
counseling practice. 2022 ASCO Annual Meeting. J Clin Oncol 40(Suppl 16),
2022.
3. Abuhadra N, Chang CC, Yam C, White JB, Ravenberg E, Lim B, Ueno NT, Litton
JK, Arun B, Damodaran S, Murthy RK, Ibrahim NK, Hortobagyi GN, Valero V,
Tripathy D, Thompson AM, Mittendorf EA, Huo L, Moulder SL, Jenq RR.
Identification and characterization of de novo TP53 mutation carriers in
Li-Fraumeni syndrome families: A single institution experience. 2021 ASCO
Annual Meeting, 2021.
4. Recio CCV, Corredor J, Dodd-Eaton E, Gutierrez-Barrera AM, Daw NC, Arun B,
Wang W. Identification and characterization of de novo TP53 mutation
carriers in Li-Fraumeni syndrome families: a single institution experience.
2021 ASCO Annual Meting, 2021.
5. Yam C, Gutierrez Barrera A, Huang D, Lin X, Litton JK, Arun B. Implications
of somatic TP53 and PIK3CA mutations in patients with metastatic breast
cancer who underwent germline BRCA testing. 2017 Annual SABCS Meeting,
2017.
6. Nielsen TO, Leung SCY, Zabaglo LA, Arun B, Badve SS, Bane AL, Bartlet JMS,
Borgquist S, Chang MC, Dodson A, Ehinger A, Fineberg S, Focke CM, Gao D,
Gown AM, Gutierrez C, Hugh JC, Kos Z, Lænkholm A-V, Mastropasqua MG, Moriya
T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T,
Salgado R, Starczynski J, Sugie T, van der Vegt B, Viale G, Hayes DF,
McShane LM. Analytical validation of a standardized scoring protocol for
Ki67 assessed on breast excision whole sections: An international
multicenter collaboration. 2017 Annual SABCS Meeting, 2017.
7. Ross JL, Woodson AH, Gutierrez Barrera AM, Litton JK, Arun B. Multi-gene
panel testing results in patients with multiple breast cancer primaries.
2017 Annual SABCS Meeting, 2017.
8. Murthy RK, Ueno NT, Symmans WF, Litton JK, Arun BK, Ibrahim NK, Alvarez RH,
Gilcrease MZ, Valero V, Tripathy D,Moulder SL. Phase II single arm study of
liposomal doxorubicin (D), evacizumab (A), and temisirolimus (T) for
treatment of triple negative early breast cancer refractory to standard
neoadjuvant chemotherapy. 2014 Annual SABCS Meeting, 2014.
9. Stauder MC, Shaitelman SF, Allen PK, Brewster AM, Arun BK, Woodward WA,
Buchholz TA, Wang LE. Gamma-ray induced mutagen sensitivity and overall
survival in young women with breast cancer. 2014 Annual SABCS Meeting:abstr
P3-08-01 (selected for poster presentation), 2014.
10. Somlo G, Frankel P, Luu T, Ma C, Arun B, Garcia A, Cigler T, Fleming G,
Harvey H, Sparano J, Nanda R, Chew H, Moynihan T, Vahdat L, Goetz M, Hurria
A, Mortimer J, Gandara D, Chen A, Weizel J. Efficacy of ABT-88 (veliparib)
in patients with BRCA-associated breast cancer. 2013 Annual SABCS
Meeting:abstr PS-16-05 (selected for poster discussion), 2013.
11. Elsayegh N, Gutierrez-Barrera A, Baum G, Muse K, Jackson M, Woddson A,
Jessica P, Kuerer H, Litton J, Arun B. Factors associated with prophylactic
mastectomy among BRCA-positive patients with no personal history of breast
cancer. 2013 Annual SABCS Meeting:abstr 977 (selected for poster
presentation), 2013.
12. Yang WT, Dryden M, Broglio K, Dawood S, Valero V, Hortobagyi G, Atchley D,
Arun B. Mammographic features of Triple-negative versus HER2+ AND ER+
breast cancers. 2007 Annual SABCS Meeting, 2007.
13. Arun B, Vuskovic M, Vasiliu D, Xu HY, Atchley D, Chambers J, Bovin N,
Sneige N, Hortobagyi GN, Hufleit M. Immunomodulatory effects of celecoxib
in patients at increased risk for breast cancer. 2007 Annual SABCS Meeting,
2007.
14. Ready K, Voguel K, Atchley D, Amos C, Solomon K, Lu K, Arun B. BRCA
mutations among women with bilateral breast cancer: mutation carrier rate
and sensitivity of the BRCAPRO model based on age at first diagnosis. 2007
Annual SABCS Meeting, 2007.
15. Mazouni C, Hall A, Anderson K, Peintinger F, Fritsche H, Andre F, Yekell S,
Arun B, Buzdar AU, Esteva F, Pusztai L, Cristofanilli M.. An early decrease
in serum HER-2/neu levels after initiation of primary chemotherapy for
HER-2 positive breast cancer indicates response to treatment. 2006 Annual
SABCS Meeting, 2006.
16. Yang WT, Dryden M, Broglio K, Meric-Bernstam F, Valero V, Arun B.
Mammographic and sonographic features of breast cancer in young women at
high genetic risk. 2006 Annual SABCS Meeting, 2006.
17. Arun B, Valero V, Logan C, Rivera E, Brewster A, Green M, Buzdar A, Browne
D, Hortobagyi GN, Sneige N.. Random periareolar fine needle aspiration
compared to ductal lavage for tissue acquisition in short-term breast
cancer chemoprevention studies. 2006 Annual SABCS Meeting, 2006.
18. Solomon TL, Vogel KJ, Atchley DP, Amos C, Valero V, Meric F, Hortobagyi G,
Arun B. High-risk precursor lesions observed in breast cancer patients who
are positive for BRCA1 or BRCA2 mutations. 2006 Annual SABCS Meeting, 2006.
19. Huflejt M, Vuskovic M, Mazouni C, Vasiliu D, Xu H, Chambers J, Buzdar A,
Arun B, Bovin N, Cristofanilli M, Pusztai L. Detection of anti-glycan
autoantibodies with printed glycan arrays in primary breast cancer:
diagnostic and predictive antibody signatures. 2006 Annual SABCS Meeting,
2006.
20. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK,
Pusztai L, Chen J-N, Clarke CH, Arun B, Hung M-C, Kuerer HM. Significant
differences in ductal fluid protein expression in healthy women versus
those with breast cancer identified by time-of-flight mass spectrometry.
2004 Annual SABCS Meeting 88(1):S189, 2004.
21. Cabioglu N, Yazici MS, Arun, B, Smith T, Hortobagyi GN, Price JE, Sahin AA.
Novel biomarkers predicting axillary lymph node metastasis in small size
breast cancer. 2004 Annual SABCS Meeting 88(1):S69, 2004.
22. Cristofanilli M, Krishnaumurthy S, Guerra L, Arun B, Walters R, Booser DJ,
Green MC, Kau S-W, Menander K, Van Wart HJ, Valero V, Hortobagyi, GN.
Advexin (Ad5CMV-p53) combined with Docetaxel (T) and Doxorubicin (D) as
induction chemotherapy (IC): significant efficacy of a novel gene-therapy
approach for patients with locally advanced breast cancer (LABC). 2004
Annual SABCS Meeting 88(1):S61, 2004.
23. Arun B, Lammey J, Broglio K, Valero V, Babiera G, Browne D, Hortobagyi GN,
Sneige N. Downregulation of Estrogen receptor expression with Celecoxib in
breast tissue of women at increased risk for developing breast cancer. 2004
Annual SABCS Meeting 88(1):S157, 2004.
24. Arun B, Dice K, Albarracin C, Rivera E, Walters R, Theriault R, Booser D,
Bast R, Cristofanili M, Sahin A, Smith TL, Hortobagyi GN. The combination
of Letrozole and Imatinib Mesylate for metastatic breast cancer. 2004
Annual SABCS Meeting 88(1):S235, 2004.
25. Moshin SK, Elledge RM, Arun B, Miller A, Wu K, Johnson K, Lamph WW, Browh
PH. Breast cancer prevention using RXR-selective retinoid (Targretin) in
high risk women initial report of a phase II randomized clinical trial.
2003 Annual SABCS Meeting 82(1):S176, 2003.
26. Arun B, Bariera G, Lammey J, Hortobagyi G, Sneige N. Phase II
chemoprevention trial of Celecoxib using ductal lavage. 2003 Annual SABCS
Meeting 82(1):S26, 2003.
27. Rivera E , Arun B, Royce M, Adinin R, Valero V, Hoelzer K, Walters R, Wade
III J, Pusztai L, Hortobagyi GN. Phase II study of Gemcitabine (G) and
Doxil (D) combination chemotherapy in patients with metastatic breast
cancer: preliminary results. 2001 Annual SABCS Meeting, 2001.
28. Pusztai L, Mendoza TR, Reuben JM, Broemeling L, Lara J, Rivera E, Arun B,
Esteva F, Valero V, Hortobagyi GN, Cleeland CS. Correlation between fatigue
and musculoskeletal symptoms and chemotherapy-induced release of
inflammatory cytokines in the blood. 2001 Annual SABCS Meeting 7, 2001.
BOOK CHAPTERS
1. Bayraktar S, Arun B. Epidemiology, Risk Factors and Prevention. In: Breast
Cancer Diagnosis and Pathology. Springer: New York, 57-87, 2016.
2. Ready K, Arun B. Breast cancer syndromes: Counseling and management. In:
Advanced Therapy for Breast Cancer. B.C. Decker Inc. Publishers: Ontario,
Canada, 2011.
3. Arun B. Hereditary breast cancer risk and genetic counseling. In: ESGO
Genetics. Springer: New York, 1-6, 2011.
4. Arun B, Ready K. Genetic predisposition to breast cancer and genetic
counseling and testing. In: Breast Cancer. 2nd. Springer: New York, 57-82,
2007.
5. Arun B, Ready K. Hereditary breast cancer genetic predisposition to breast
cancer [and genetic counseling and testing. In: Breast Cancer. Springer
Science+Business Media: New York, 2007.
6. Bottom K, O'Leary M, Sheaffer J, Phillips M, Shu X-O, Arun B. Cancer
epidemiology in older adolescents and young adults 15 to 29 years of age,
including SEER incidence and survival. In: Breast Cancer. National Cancer
Institute, NIH Pub No. 06-5767: Bethesda, MD, 111-121, 2006.
7. Arun B. Breast cancer risk assessment and management. In: Breast Cancer.
2nd. B.C. Decker Inc, 2005.
8. Arun B, Kuerer H. Breast cancer risk assessment and management. In: Breast
Cancer. 2nd. B.C. Decker Inc. Publishers: Ontario, Canada, 2005.
9. Arun B, Strong L. Breast cancer genetic syndromes. In: Advanced Therapy of
Breast Disease. 2nd. B.C. Decker Inc. Publishers: Ontario, Canada, 75-83,
2004.
10. Arun B. Ductal lavage in risk reduction. In: Advanced Therapy of Breast
Disease. 2nd. B.C. Decker Inc. Publishers: Ontario, Canada, 113-119, 2004.
11. Arun B, Hortobagyi GN. Chimioterapia adjuvant| Õi hormonoterapia cancerului
mamar primar. Chapter 17. In: Tratamentul Conservator al Cancerului Mamar
Incipient. Editura Universitar| Carol Davila, 275-295, 2003.
12. Arun B, Kessler CM. Clinical manifestations and therapy of the hemophilias.
In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th,
815-824, 2001.
13. Arun B, Philips M. Breast cancer in adolescents and young adults. In: AYA
Monograph, 2000.
Read More
Less
GRANT & CONTRACT SUPPORT
Title:Genetic risk prediction in primary careFunding Source:The University of
Texas at DallasRole:Multi Principal Investigator (Clinical)
Title:Increasing genetics services availability to underserved high risk breast
cancer patientsFunding Source:Susan G. Komen Breast Cancer
FoundationRole:Principal Investigator
Title:A model for individualized risk prediction of contralateral breast
cancerFunding Source:The University of Texas at DallasRole:Co-Investigator
Title:Cancer prevention agent development program: early phase clinical research
consortiumFunding Source:NIH/NCIRole:Co-Investigator
Title:Identification and characterization of variants of uncertain significance
(VUS) in BRCA1 and BRCA2Funding Source:Sister Institute Network
FundRole:Principal Investigator
Title:Hormone regulation of tumor microenvironment in estrogen receptor-positive
breast cancer by extracellular vesicle microRNAFunding
Source:DOD/Congressionally Directed Medical Research Programs
(DOD/CDMRP)Role:Principal Investigator
PATIENT REVIEWS
--------------------------------------------------------------------------------
REQUEST AN APPOINTMENT
Whether you are ready to make an appointment now or have questions for our
expert team, we are standing by to help.
Learn more
RELATED LINKS
* CARE CENTERS AND CLINICS
* DEPARTMENTS AND DIVISIONS
* LABS
CLINICAL TRIALS
Our patients have access to clinical trials offering promising new treatments
that cannot be found anywhere else.
Learn more
HELP #ENDCANCER
GIVE NOW
Your gift will help make a tremendous difference.
Donate
DONATE BLOOD
Giving blood and platelets provides hope for cancer patients who depend on the
generosity of donors like you.
Learn more
VOLUNTEER
Change the lives of cancer patients by giving your time and talent.
Stay Connected
Subscribe to Publications
* Explore
* Patients & Family
* Prevention & Screening
* Donors & Volunteers
* For Physicians
* Research
* Education & Training
* Clinical Trials
* Languages
* About
* About MD Anderson
* Careers
* Blog
* Newsroom
* For Employees
* Title IX Reporting (Sexual Misconduct)
* Price Transparency
* Finding Your Way
* Our Doctors
* Locations
* Directions
* Sitemap
* DIGITAL ACCESSIBILITY
* Accessibility Policy
* GET IN TOUCH
*
Call
1-855-690-1332
*
Ask a question
* More
* Privacy Policy
* Legal Statement & Policies
* Reports to the State
* Emergency Alert Information
* State of Texas Links
* MD Anderson Cancer Network
* Vendors & Suppliers
© 2024 The University of Texas MD Anderson Cancer Center